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Kaposi’s sarcoma-associated herpesvirus (KSHV), the only rhadino- or γ2-herpesvirus of humans, is 
associated with Kaposi’s sarcoma (KS) and two B cell proliferative malignancies, primary effusion 
lymphoma (PEL) and a variant of multicentric Castleman’s disease (MCD). As routes of primary 
infection, dissemination through the host, and development of virus-associated pathologies are at 
least partially shaped by viral cell and tissue tropism, it is crucial to understand the contribution of 
distinct viral glycoproteins and cellular receptor interactions to cell type-specific infection. In this 
context, the present thesis focuses on members of the Eph family of receptor tyrosine kinases, which 
were shown to play a role in KSHV infection of various adherent cell lines. While the KSHV gH/gL 
glycoprotein complex exhibits the highest affinity for EphA2, additional A-type Ephs have been 
described as interaction partners of KSHV. Even though the gH/gL-Eph interaction was subject of 
various studies, key questions regarding the role of Ephs in KSHV tropism and pathology remained 
unanswered. We therefore aimed to identify amino acid residues on the KSHV gH/gL complex that 
critically mediate the Eph interaction, create Eph detargeted virus recombinants mutated in the 
identified amino acid residues, and characterize the Eph usage on BJAB cells, as model for cell-to-cell 
transmission of KSHV into B cells. Similar to KSHV, the related rhesus monkey rhadinovirus (RRV) 
interacts with Eph receptors while exhibiting differing affinities for individual Eph family members. 
Comparison of the two viruses allowed us to identify conserved amino acid residues in the 
N-terminal domain of gH which are critical for the gH/gL-Eph interaction. Mutation of these amino 
acids in KSHV and RRV recombinants abrogated the viral interaction with Eph receptors and allowed 
us to analyze the cell type-specific contribution of the Eph family to KSHV and RRV infection. This 
system was also employed in our second study which identified two additional A-type Ephs as 
functional KSHV and RRV receptors on BJAB cells. The role of EphA5 and EphA7 in KSHV cell-to-cell 
transmission and RRV cell-free infection was demonstrated using CRISPR/Cas9-mediated knockout. 
We furthermore addressed the question whether additional cellular, Eph-independent interaction 
partners of the gH/gL complex shape the rhadinoviral infection of different cell types. We identified 
the Plexin domain containing proteins 1 and 2 (Plxdc1/2) as specific interactors for RRV, but not 
KSHV, and characterized a crucial Plxdc-interaction motif in close proximity to the identified 
Eph-interacting residues on RRV gH. Receptor function of Plxdcs was demonstrated by lentiviral 
overexpression of Plxdc1 and 2 in target cells and a Plxdc-detargeted RRV deletion mutant.  
Collectively, the present studies identify additional A-type Eph members as functional receptors for 
KSHV and RRV, characterize the role of a novel family of gH/gL-interacting proteins for RRV infection, 
and underline the importance of the N-terminal domain of the rhadinoviral gH as conserved 
receptor-binding domain, which mediates the interaction of KSHV and RRV with Eph receptors and 








Das Kaposi-Sarkom-Herpesvirus (KSHV), das einzige Rhadino- oder γ2-Herpesvirus im Menschen, ist 
mit dem Kaposi Sarkom (KS) und zwei B-Zell-Lymphomen, dem primären Effusionslymphom und der 
multizentrischen Castleman-Erkrankung, assoziiert. Da der Mechanismus der Primärinfektion, die 
Ausbreitung im Wirt und die Entstehung Virus-assoziierter Erkrankungen zumindest teilweise durch 
den viralen Zell- und Gewebetropismus bestimmt werden, ist es entscheidend den Beitrag 
spezifischer Interaktionen zwischen viralen Glykoproteinen und zellulären Rezeptoren zur Infektion 
unterschiedlicher Zelltypen zu verstehen. Der Fokus dieser Arbeit liegt hierbei auf der Familie der Eph 
Rezeptortyrosinkinasen, die an der Infektion diverser adhärenter Zelllinien beteiligt sind. Indes der 
KSHV gH/gL Glykoproteinkomplex die höchste Affinität für EphA2 aufweist, wurden weitere Eph 
Rezeptoren des A-Typs als Bindepartner von KSHV beschrieben. Obwohl die gH/gL-Eph Interaktion 
Gegenstand verschiedener Studien war, gibt es weiterhin unbeantwortete Fragen bezüglich der Rolle 
von Eph Rezeptoren für den KSHV Tropismus und KSHV-assoziierte Pathologien. Unsere Zielsetzung 
lag demnach in der Identifikation von Aminosäuren in KSHV gH/gL, welche essentiell für die 
Eph-Interaktion sind, in der Konstruktion von rekombinanten Viren mit Mutationen in den 
identifizierten Aminosäuren, sowie in der Charakterisierung der Eph Rezeptor Nutzung auf BJAB 
Zellen, einem Modell für die Zell-assoziierte KSHV Infektion von B-Zellen. Analog zu KSHV interagiert 
das verwandte Rhesusaffen Rhadinovirus (RRV) mit Eph Rezeptoren, zeigt hierbei jedoch 
abweichende Affinitäten für einzelne Mitglieder der Eph Familie. Durch Vergleiche zwischen beiden 
Viren konnten wir konservierte Aminosäuren in der N-terminalen Region von gH identifizieren, 
welche essentiell für die gH/gL-Eph Interaktion sind. Mutation dieser Aminosäuren in KSHV und RRV 
verhinderte die Interaktion mit Eph Rezeptoren und ermöglichte uns die Analyse des Zelltyp-
spezifischen Beitrags von Eph Rezeptoren zur KSHV und RRV Infektion. Dieses System kam außerdem 
in unserer Studie zum Einsatz, die zwei weitere Eph Rezeptoren des A-Typs als funktionelle KSHV und 
RRV Rezeptoren auf BJAB Zellen charakterisierte. Die Funktion von EphA5 und EphA7 in der KSHV 
Zell-Zell Übertragung, sowie in der zellfreien RRV Infektion wurde durch Knockout mit Hilfe der 
CRISPR/Cas9 Methode nachgewiesen. Ferner beschäftigten wir uns mit der Frage, ob weitere, Eph-
unabhängige Interaktionspartner des gH/gL Komplexes die Infektion verschiedener Zelltypen durch 
Rhadinoviren beeinflussen. Wir identifizierten die Plexin domain containing Proteine 1 und 2 
(Plxdc1/2) als spezifische Interaktionspartner von RRV im Gegensatz zu KSHV und beschrieben ein 
essentielles Plxdc-Interaktionsmotiv nahe dem Eph-Interaktionsmotiv in RRV gH. Die Plxdc-
Rezeptorfunktion wurde mittels lentiviraler Überexpression sowie mit Hilfe von zur Plxdc-Bindung 
unfähigen RRV Deletionsmutanten nachgewiesen. Zusammengenommen beschreiben die 
vorliegenden Studien weitere Eph Rezeptoren vom A-Typ als funktionelle Rezeptoren für KSHV und 
RRV, charakterisieren die Funktion einer neuen Rezeptorfamilie für die RRV Infektion und 
verdeutlichen die Bedeutung der N-terminalen Region des rhadinoviralen gHs als konservierte 
Rezeptorbindedomäne, welche die Interaktion von KSHV und RRV mit Eph Rezeptoren und die 
Interaktion von RRV mit Plxdc Rezeptoren vermittelt. 





I.1 The pathogen KSHV - A historical view 
 
The Kaposi’s sarcoma-associated herpesvirus (KSHV) or human γ-herpesvirus 8 (HHV-8) is one 
of the seven human oncogenic viruses (i.e. Epstein-Barr Virus (EBV), Hepatitis B and C Virus (HBV/ 
HCV), Human Papillomavirus (HPV), Human T-lymphotropic virus (HTLV), KSHV, and Merkel cell 
polyomavirus (McPyV)) characterized today
1
. Dating back only 26 years, the identification of KSHV 
was a recent event in the history of infectious diseases. Nevertheless, cases of KSHV-associated 
diseases, namely the Kaposi’s sarcoma (KS) in elderly men, were reported as early as 1872 by the 
Hungarian physician Moritz Kaposi (Figure 1) as “idiopathic multiple pigmented sarcoma of the skin”
2
. 
In addition to the initially described KS variant, classified today as classic or sporadic KS
3
, case reports 
in the late 1940s started to document a distinct form of KS which is prevalent in Sub-Saharan Africa 
and most commonly occurs in 
young males
4–6
. In children, this 
form, now generally referred to as 
endemic KS
3
, often presents with 
lymphadenopathy involving 
multiple nodes and an aggressive 
clinical course in addition to typical 
skin lesions
7
. However, KS did not 
gain a broader attention until the 
onset of the human immuno-
deficiency virus and acquired 
immune deficiency syndrome 
(HIV/AIDS) epidemic, and 
associated reports of a highly 
aggressive KS form in HIV
+
 men 
who have sex with men in 1981
8
, 
which is classified today as AIDS-
related KS or epidemic KS
3
. While 
the link between immuno-
suppression and development of KS 
is well established by now, the first 
Figure 1 Cover of the February 2018 Lancet Oncology edition 
depicting Moritz Kaposi, who first described the skin tumor 
today referred to as Kaposi`s sarcoma. Cover art by Daniёl 
Roozendaal (www.danielroozendaal.com). 
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AIDS-KS cases occurred before the connection between AIDS-related immunodeficiency and KSHV as 
opportunistic infection was established. Today, iatrogenic KS, the fourth form of KS in recipients of 
solid-organ allografts, is recognized to correlate with the level of immunosuppression after 
transplantation9, and both the classic as well as the endemic form of KS are suggested to rely on 
impaired immune function either due to an aging immune system and related “immune 
senescence”10 or due to chronic infections and malnutrition11. Nevertheless, KS was reported to occur 
significantly more frequent in patients with AIDS than in other immunosuppressed patient groups12–14 
which could hint to a possible role for HIV co-infection that exceeds the described 
immunosuppression. The marked dependence of KS development on HIV co-infection was further 
underlined by the introduction of combination antiretroviral therapy (cART) for the treatment of HIV 
infection in 1996, which – without further treatment of the KSHV infection – dramatically decreased 
the incidence of AIDS-KS15.  
In 1994, led by epidemiological studies which suggested an infectious agent independent of 
HIV as cause for KS, directed attempts to detect and analyze pathogen DNA in KS lesions resulted in 
the identification of KSHV, a novel human herpesvirus in the γ2- or rhadinovirus lineage16. Soon after, 
KSHV infection was additionally associated with two lymphoproliferative disorders, the primary 
effusion lymphoma (PEL)17 and one form of multicentric Castleman disease (MCD)18.  
Like KS, KSHV-associated MCD (KSHV-MCD) can occur in the context of HIV co-infection but is 
not restricted to HIV+ patients, whereby HIV-independent MCD is most prominently seen in KSHV-
endemic regions19,20. Classical symptoms of KSHV-MCD include enlarged lymph nodes and systemic 
symptoms, such as fever, spleno- and hepatomegaly and effusions21. Patients with KSHV-MCD 
commonly present with KS as well. Additionally, in some cases progression of MCD to aggressive 
diffuse large B cell lymphoma has been reported22.  
PEL, formerly called “body cavity lymphoma”, presents with malignant effusions in e.g. 
abdominal, pericardial or pleural cavities without solid tumor mass in most cases, even though extra-
cavitary lesions have been described23,24. Similar to other KSHV-associated malignancies, PEL most 
commonly occurs in the context of immunosuppression and EBV co-infection has been detected in 
the majority of cases17,25. Even though treatment of PEL patients with cART led to complete remission 
in some cases26–28 (as seen for KS), prognosis is extremely poor as PEL is generally resistant to 
chemotherapy and prospective clinical trials are difficult due to the low case numbers29.  
In recent years, the KSHV inflammatory syndrome (KICS) was described as a fourth KSHV-
associated disease. While the clinical symptoms, including elevated levels of viral and human 
interleukin-6 and interleukin-10 leading to a systemic inflammation, resemble KSHV-MCD, KICS 
presents without generalized lymphadenopathy or clinical evidence of MCD in lymph nodes30. 
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I.2 KSHV tropism 
 
I.2.1  Host tropism on an evolutionary scale  
 
While the host range of individual members of the order Herpesvirales is highly restricted, the 
over 200 herpesviruses described to date were identified in a broad spectrum of host organisms, 
including not only vertebrates (ranging from fish to primates
31,32
) but also invertebrates (such as 
oysters
33
). The members of the family Herpesviridae fall in three taxonomically divided subfamilies, 
α-, β- and γ-herpesviruses. While assignment to subfamilies was initially based on distinct biological 




Phylogenetic analysis of 48 virus species indicated co-speciation and co-evolution of 
herpesviruses with their respective host for lineages from all subfamilies based on branching 
patterns in phylogenetic trees of mammalian hosts and their respective herpesviruses
35–37
. While the 
diversification time point for α-, β- and γ-herpesvirinae was approx. 200 million years ago, the 
emergence of major genera within the subfamily dates back to at least the mammalian radiation 60-
80 million years ago
36,38
. Consequently, human pathogenic members of the three subfamilies and 
even within the γ-herpesvirus subfamily (e.g. EBV and KSHV) are genetically more divergent than 
members of the same genus – in case of KSHV rhadinovirinae – from different species (Figure 2). The 
genus rhadinovirinae can be further sub-divided into two lineages, the rhadinoviruses 1 (RV1), which 
contains KSHV and rhadinoviruses 2 (RV2), without a described human pathogenic member. The RV1 
lineage of Old World monkeys comprises the macaca (M.) retroperitoneal fibromatosis–associated 
herpesviruses (RFVHs) identified in M. mulatta and M. nemestrina
39
, as well as the recently isolated 
colobine γ-herpesvirus 1 (CbGHV1)
40
 and rhadinovirus sequences obtained from different African 
green monkey (Chlorocebus aethiops) species (namely RV1caa [Chlorocebus aethiops aethiops], 
RV1cap [Chlorocebus aethiops pygerythrus], RV1cas [Chlorocebus aethiops sabaeus])
41
. The RV2 
lineage includes RV2mac strains from rhesus macaques (rhesus macaque rhadinovirus [RRV, 
RV2mmu
42,43
], M. mulatta]), Japanese macaques (Japanese macaque rhadinovirus
44
, M. fuscata), 
Crab-eating macaques (RV2mfa
45,46
, M. fascicularis) and southern pig-tailed macaques (RV2mne
46
, M. 
nemestrina) as well as viruses of the Chlorocebus aethiops species described above (RV2caa, RV2cap, 
RV2cas
41
). While non-human primate rhadinoviruses of the RV1 lineage are genetically closer related 
to KSHV than members of the RV2 lineage, most studies in non-human primates focused on the M. 
mulatta - RRV analogue model system as detailed below.  
 




Figure 2 Phylogenetic trees of γ-herpesviruses. A) Amino acid sequence-based phylogenetic analysis of 
eight genes from ten γ-herpesviruses demonstrates the phylogenetic relationship of the γ1-herpesviruses/ 
lymphocryptoviruses (EBV, RLV, CHV3) and the γ2-herpesviruses/ rhadinoviruses (HHV8/ KSHV, RRV, HVA, 
HVS, EHV2, AHV1, PLHV1) of different mammalian species. The analyzed genes have sufficiently 
conserved orthologues in all sequenced genomes of mammalian and avian α-, β- and γ-herpesviruses36,38. 
B) Nucleotide sequence-based phylogenetic analysis of the genomes of seven non-human primate γ2-
herpesviruses and EBV as outgroup depicts the two lineages (RV1/ RV2) of γ2-herpesviruses. Modified 
figures from McGeoch et al., 200537 (A) and Dhingra et al., 201940 (B). Abbreviations: EBV: Epstein-Barr 
virus, RLV: rhesus lymphocryptovirus, CHV3: Callitrichine herpesvirus 3, HHV8/ KSHV: Human γ-
herpesvirus 8/ Kaposi’s sarcoma-associated herpesvirus, RRV: rhesus monkey rhadinovirus, HVA: 
Herpesvirus ateles, HVS: Herpesvirus saimiri, EHV2: Equid herpesvirus 2, AHV1: Alcelaphine herpesvirus 1, 
PLHV1: Porcine lymphotropic herpesvirus 1, JMRV: Japanese macaque rhadinovirus, MneRV2: Macaca 
nemestrina rhadinovirus 2, CbGHV1: colobine γ-herpesvirus 1, RFHVMn: retroperitoneal fibromatosis–
associated herpesviruses of Macaca nemestrina. 
 
I.2.2  Cell and tissue tropism within the host 
 
Reminiscent of the wide range of host species of the family Herpesviridae, individual members 
exhibit a broad cell and tissue tropism, both in vivo and in vitro. As understanding the viral life cycle, 
spread through the host organism, and associated diseases relies on detailed knowledge of this 
tropism, we need to identify molecular factors and interactions that determine and shape these 
preferences. While KSHV can infect numerous cell types in vitro47,48, KSHV transmission in vivo is 
believed to occur mainly through saliva, and subsequent infection of the oral mucosa48. 
Epidemiological studies and molecular evidence support this mode of transmission for early 
childhood infections in endemic regions49–52, while sexual transmission of KSHV, particularly in men 
who have sex with men, plays a more substantial role in non-endemic areas53–56. Nevertheless, the 
initial target cell types infected by KSHV, the cellular origin of KSHV-associated diseases, and 
potential intermediate target cells that could influence KSHV spread and dissemination throughout 
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the host are not well characterized. Potential initial target cells for the transmission through the 
salivary-mucosal route include cells of the local oral epithelium and submucosa, e.g. keratinocytes, 
monocytes, macrophages, B lymphocytes and endothelial cells
57–62
. For instance, it has been 
demonstrated that primary tonsillar B cells can be productively infected by KSHV, leading to 
proliferation and plasmablast differentiation
58,63
. B cells are widely recognized as the most likely 
reservoir of KSHV lifelong persistence in the host, even though primary B cells and established B cell 
lines are largely refractory to cell-free KSHV infection in vitro. Notably, this refractoriness can be 
overcome in cell-to-cell transmission systems
64
, raising questions about a potential role of cell-
associated virus in host colonization in vivo. Additionally, primary keratinocytes are susceptible to 
KSHV infection in vitro and various reports demonstrated the presence of KSHV in skin 
keratinocytes
65,66
 and the oral epithelium in vivo
52,67,68
. Interestingly, terminal differentiation of KSHV 
infected basal keratinocytes was shown to induce lytic replication
57,61
 providing a possible rationale 
for oral KSHV shedding as well as a putative additional reservoir of latent KSHV in the host. 
 Similar to initial target cells, the cellular origin of KSHV-associated diseases, in particular KS is 
still under discussion. While spindle cells, the primary cell type found in KS, were initially thought to 
be of polyclonal endothelial origin
69,70
, subsequent studies demonstrated that in addition to lineage 
markers of blood and lymphatic endothelial cells, spindle cells can express markers of macrophages, 
dendritic cells, and smooth muscle cells
71–77
. Additionally, a recent study suggested oral mesenchymal 
stem cells as origin of AIDS-KS spindle cells based on the expression of neuroectodermal stem cell 
marker Nestin and oral mesenchymal stem cell marker CD29 in spindle cells and induction of 
mesenchymal-to-endothelial transition after KSHV infection of mesenchymal stem cells
78
.  
As the terminology indicates, the cell type giving rise to KSHV-associated B cell malignancies is 
less controversial. However, various studies involving different B cell lines as well as primary B cells, 
including tonsillar B cells and activated peripheral blood cells
79,80
, could not decisively answer the 
question which type of B cells, B cell progenitors or stages of B cell development are susceptible to 
KSHV. Even though in KSHV-MCD, infected lymphocytes most closely resemble the plasmablast stage, 
both regarding specific transcription factors as well as expression of cell surface markers, they do not 
harbor somatic mutations in the rearranged Ig genes, which suggests naïve, pre germinal-center (GC) 
B cells
81
 or possibly IgM memory B cells
63
, as cellular origin. KSHV-infected B cells from PEL on the 
other hand do exhibit somatic hypermutations and Ig class-switching, compatible with GC 
maturation, at least in the context of EBV co-infection
82,83
. A study by Hassman et al.
63
 suggested the 
infection of IgMλ tonsillar B cells as common initial target population for both malignancies, followed 
by KSHV-driven differentiation of infected B cells, which would also be compatible with the 
phenotype displayed for example by EBV-negative PEL cell lines, BC-3 and BCBL-1
63,82
. According to 
this model, naïve, polyclonal B cells – of a until now not specified phenotype – could form the latent 
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KSHV reservoir and develop distinct lymphoproliferative diseases depending on co-factors, such as 
HIV or EBV co-infection, immune deficiency or aging. Studies concerning the cellular origin of KSHV-
associated B cell malignancies are hampered by the general refractoriness of B cells to cell-free KSHV 
infection in vitro as well as the broad potential range of target B cell types and developmental stages 
in vivo. Interestingly, a recent publication identified a human B cell line, MC116 cells, which could be 
infected with cell-free KSHV at high virus concentrations84 and may therefore serve as model for 
cell-free KSHV infection of human B lymphocytes in future studies.  
 
I.3 The KSHV life cycle 
 
Herpesviruses are enveloped viruses, carrying a large double-stranded (ds) DNA genome, 
which encodes for up to 200 genes, encapsulated in an electron-dense icosahedral capsid which in 
turn is surrounded by a proteinaceous tegument layer, and a lipid bilayer harboring diverse 
glycoproteins that mediate the initial virus-host interactions32. Specifically, the 165 to 170kb KSHV 
genome encodes for over 90 identified proteins, many of which are conserved within the herpesvirus 
family. Open reading frames (ORFs) uniquely found in KSHV and simian Old World rhadinoviruses are 
denoted “K” genes48. Additionally, in recent years, an increasing number of small non-coding RNAs, 
microRNAs and a polyadenylated nuclear RNA have been identified in the KSHV genome (Figure 3)48. 
 
 
Figure 3 Genome map of the Kaposi’s sarcoma-associated herpesvirus. Open reading frames are 
indicated by arrows. Conservation of genes in related α-, β- or γ-herpesviruses is indicated by color. Figure 
taken from Field’s Virology (Damania, B. and Cesarman, E. Kaposi`s Sarcoma-Associated Herpesvirus)48.  
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Prototypic for herpesviruses, the KSHV life cycle (Figure 4) can be divided into two distinct 
phases, latent infection and lytic reactivation. In general, latency is the default mode upon primary 
infection in vitro and in vivo with sporadic bursts of lytic reactivation provoked by various triggers. 
KSHV enters target cells in a sequential, multistep process, which consists of, most likely, cell type-
independent attachment to target cells followed by the interaction of viral glycoproteins with specific 
cellular receptors48. Upon binding to the respective cell-surface molecules, signaling cascades and 
subsequent entry pathways are triggered to induce the uptake of KSHV virions into the cell85. While 
multiple KSHV receptors have been described, as detailed below, inhibition of individual 
glycoprotein-receptor interactions is not sufficient to completely abrogate KSHV infection86–88, 
indicating an at least partially redundant role of different entry receptors and pathways. 
Upon entry of viral capsids into target cells, most likely by macropinocytotic or clathrin-
mediated endocytotic uptake and fusion of the viral envelope with endosomal membranes under low 
pH conditions85,89–92, capsids are shuttled to the nucleus via directed transport along the microtubule 
cytoskeleton48,93. Subsequently, the capsid is disassembled and the viral genome is released into the 
nucleus, where it is circularized, chromatinized and maintained in an episomal state during latency94. 
Latency is characterized by the production of a limited subset of viral gene products (e.g. the latency 
associated nuclear antigen (LANA, ORF73), viral (v)Cyclin (ORF72), vFLIP (ORF71) and kaposins A, B, 
and C) as well as the 12 viral pre-microRNAs95–97 and maintenance of a limited genome copy number, 
evenly distributed to daughter cells during division98,99. Various physiological stimuli, such as hypoxia 
and oxidative stress100–102 can trigger sporadic lytic reactivation leading to a temporally regulated 
gene expression cascade of immediate early, early and late genes103–107. In KSHV infection, expression 
of the replication and transcription transactivator (RTA)/ORF50, the “lytic switch” protein, is both 
indispensable and sufficient to initiate the lytic replication cycle and activates various cellular and 
viral promoters108,109. After expression of all lytic gene classes, viral progeny are assembled by 
packaging of replicated genomes into newly synthesized capsids, engulfment of DNA-containing 
capsids in viral tegument proteins and subsequent incorporation in a host-derived membranous 
envelope containing KSHV glycoproteins. In analogy to other herpesviruses the mature envelope is 
most likely acquired through the use of physiological vesicular transport systems, such as the trans-
Golgi network (HSV)110–112 or recycling endosomes (HCMV)113. Subsequently, mature virions are 
released by fusion of vesicle membranes with the plasma membrane. 
 




Figure 4 KSHV virion structure and life cycle. The different components of the KSHV virion are indicated. 
Upon interaction of viral glycoproteins with cellular attachment factors and entry receptors, viral particles 
enter target cells via clathrin-mediated endocytosis or macropinocytosis. Viral capsids are released in the 
cytoplasm after pH-dependent fusion of the viral envelope with endosomal membranes and transported 
to the nucleus. Latency, characterized by episomal genomes tethered to host chromosomes via LANA and 
expression of a limited number of KSHV gene products is the default outcome after release of the viral 
genome into the nucleus in most, if not all experimental setups. Upon RTA-dependent initiation of the 
lytic cycle, viral DNA and proteins are synthesized and genomes are packages in newly assembled capsids. 
Mature virions containing the viral envelope, tegument and glycoproteins are formed and transported 
(most likely in host-derived compartments) to the plasma membrane where they are released. 
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I.4 Virus - host interactions in KSHV entry 
 
I.4.1 Part I – The viral glycoproteins 
 
At least seven KSHV glycoproteins, namely ORF8/glycoprotein B (gB), ORF22/gH, ORF39/gM, 
ORF47/gL, ORF53/gN, ORF4/KCP, K14/vOx2 and K8.148,114–116 are associated with the KSHV envelope. 
Similar to other herpesviruses, these glycoproteins can be divided into two categories, proteins 
specific for KSHV and Old World simian rhadinoviruses and ones that share homology with 
glycoproteins of other members of the α-, β- and γ-herpesvirinae. 
Common to all herpesviruses is the core fusion machinery, consisting of the gH/gL glycoprotein 
complex as fusion activator and interactor with cellular receptors and the driver of membrane fusion 
gB117–119. These glycoproteins consequently represent the best characterized contributors to KSHV cell 
entry, partially derived from homology studies of other herpesviruses. gB is synthesized as a 110kDa 
precursor protein, which is subsequently cleaved at a consensus furin protease cleavage site and 
modified by N-linked and O-linked glycosylation giving rise to two disulfide-linked subunits of 59kDa 
and 75kDa120. The KSHV gH/gL heterodimeric complex consist of the approx. 80kDa gH and the 
approx. 16kDa gL, which depends on the expression of gH for efficient expression, processing and 
incorporation into the virion121. By similarity, receptor-glycoprotein complexes formed by gH/gL and 
the respective cellular receptors interact with the KSHV fusion executer gB and trigger structural 
changes in the metastable prefusion state which ultimately lead to fusion of the viral and cellular 
membranes leaving gB in a stable postfusion state122. Even though the basic components of this core 
fusion machinery are conserved between all herpesviruses, the recruitment of additional non-
conserved viral proteins or cellular receptors shapes the differences and virus-specific cell tropism 
exhibited within the herpesvirus family117,123. 
The KSHV complement control protein (KCP/ORF4) shares homology with herpesviral and 
cellular regulators of complement activation. All three proposed KCP isoforms inhibit the 
complement pathway at the C3-convertase step and are able to interact with heparan sulfate115,124,125. 
Functional characterization of glycoproteins M and N, named according to their homologs found in 
other herpesviruses and proposed to have a conserved function as fusion inhibitors126, is still rather 
sparse.  
K8.1 and K14 on the other hand do not have described homologs in α- and β-herpesviruses. 
However, K14 is a homolog of the mammalian CD200/OX2 and its suggested functions encompass a 
similar role in immunomodulation in addition to potential roles in cell adhesion116. K8.1A, one of two 
alternatively spliced reading frames encoded by the K8.1 gene127, is the most abundant glycoprotein 
incorporated into the viral envelope128,114,129 and highly immunogenic in the host130,131. While a recent 
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study suggested a critical role of K8.1A for the B cell tropism of KSHV132, it appears to be dispensable 
for infection of endothelial cells and 293 cells133,134 and a B cell specific receptor is still lacking. While 
ORF68 was initially classified as glycoprotein in the viral envelope114 subsequent studies 
demonstrated its role as a DNA binding protein, involved in KSHV genome encapsidation135, making a 
function in KSHV entry unlikely. 
 
I.4.2  Part II – The cellular receptors 
 
An increasing number of cellular interaction partners of KSHV glycoproteins have been 
identified that potentially contribute to the cell and tissue tropism of KSHV (Figure 3).  
Members of the Heparan sulfate proteoglycan (HSPG) family were the first cellular factors 
shown to be involved in the binding of KSHV to target cells133,136. While the role of HSPGs in KSHV 
attachment was initially attributed to the interaction with KSHV glycoproteins K8.1A133 and gB136, 
further viral glycoproteins, namely the gH/gL glycoprotein complex121 and ORF4/KCP115,125 have 
subsequently been described as interaction partners of HSPGs. The redundancy of the KSHV-HSPG 
interaction reflects the importance of proteoglycans for the attachment of KSHV to target cells. Using 
HSPGs for initial attachment is comprehensible considering its promiscuous expression on the 
majority of cell types – with the exception of e.g. B cells79. The rather unselective virus adhesion and 
potential concentration on the cell surface is then followed by the – most likely – cell type-
dependent interaction of viral glycoproteins with specific cellular receptors.  
Similar to HSPGs, integrins – the second class of KSHV interacting cellular receptors – are 
widely expressed on a range of cell types and are implicated in the attachment or entry process of 
several enveloped as well as non-enveloped viruses137. Initially, integrin α3β1 was shown to mediate 
KSHV infection of Chinese hamster ovary cells via interaction with a classical Arg-Gly-Asp (RGD) 
binding motif in the N-terminal ectodomain region of KSHV gB88,138. However, while integrin α3β1 
belongs to the laminin-binding, RGD-independent integrin (group II) subfamily139, the RGD motif in 
KSHV gB suggested the involvement of RGD-specific (group I) integrins in the gB-mediated cell 
adhesion. Indeed, αVβ3, a group I integrin receptor, was identified as direct interaction partner of the 
RGD motif on KSHV gB, whereas this study did not observe interaction of KSHV gB with integrin 
α3β1140. Subsequently, the presence of an additional group I integrin (αVβ5) in a multimolecular 
complex was demonstrated upon KSHV infection141. 
In contrast to the binding to HSPGs, this gB-integrin interaction may exceed a mere role in 
attachment and is thought to trigger cellular signaling cascades that ultimately lead to the 
internalization of the viral particle (detailed in Figure 5). While the importance of integrins for KSHV 
infection has been demonstrated for various cell types (reviewed in 142), a recent study suggested an 
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infection mechanism which is independent of integrin α3β1, αVβ3 and αVβ5 but relies on HSPG (for 
attachment) and on the interaction with another cellular receptor family, the erythopoetin-
producing human hepatocellular (Eph) receptors143. One member of this family, EphA2, was already 
identified as receptor for the KSHV gH/gL glycoprotein complex by Hahn et al. in 201286. 
Subsequently, the importance of the gH/gL-EphA2 interaction was verified in several studies that 
characterized cell type-specific effects, activation of signaling pathways and induction of uptake 
mechanisms86,143–149. While within the Eph family KSHV gH/gL exhibits the highest affinity for EphA2, 
recent reports demonstrated that other A-type members of the Eph family, e.g. EphA4 and EphA5, 
can functionally substitute for EphA2 upon overexpression in certain settings143,150. In general, the 
ability of KSHV gH/gL to bind a broad range of Eph receptors may indicate a redundant function of 
the Eph family in KSHV infection conveying specificity at least partially through absolute expression 
levels as well as the ratio of expression between different Eph members.  
Interestingly, HSPG as well as EphA2 are not expressed on most B cell lines, which correlates 
with poor susceptibility of these cell lines in vitro. However, while stimulation of HSPG expression on 
BJAB cells, a widely used B cell line, enhanced binding of KSHV to the cell surface it did not allow for 
efficient infection79 which indicates the need of additional cellular factors crucial for the cell-free 
infection of B cells in vitro. In accordance with these observations, a recent publication identified 
K8.1A as critical for infection of MC116 cells (a B cell line marginally permissive for infection with cell-
free KSHV) and tonsillar B cells and determined this function to be independent of the K8.1A-HSPG 
binding132. One cellular receptor described to mediate KSHV infection of activated B cells, dendritic 
cells, macrophages, and monocytes is the Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN)80,87, a C-type lectin receptor mainly expressed on dendritic cells and 
certain types of macrophages151–153. DC-SIGN recognizes viral glycoproteins modified with high 
mannose sugars, such as KSHV gB, via a carbohydrate recognition domain (CRD)153–155 which also 
facilitates the interaction with its physiological ligands, the intracellular adhesion molecules 
(ICAMs)156. Interestingly, DC-SIGN has already been described to play a role in the infection of human 
dendritic cells by flaviviruses157–159 and to facilitate the infection of HIV-1 permissive cells in trans by 
“transporting” attached virus to CD4+ T cells, the intended target cells, during physiological dendritic 
cell migration160,161. As DC-SIGN expression on dendritic cells also mediates dendritic rolling on 
endothelial cells151, one of the KSHV target cell types in vivo, the interaction of gB with DC-SIGN might 
play a similar role in KSHV infection, enabling the “shuttling” and spread of KSHV throughout the host 
to the intended reservoir cell types. 




Figure 5 Receptor interactions and signaling events leading to KSHV entry as characterized on human 
foreskin fibroblasts (HFF) and human dermal microvascular endothelial cells (HMVEC-d). Processes 
shown in HFF are indicated by dashed lines, processes shown in HMVEC-d are indicated by solid lines. On 
HFF, interaction of gB with integrin α3β1 via a classical RGD motif was reported to induce phosphorylation 
of focal adhesion kinase (FAK) which led to the activation of Src and Phosphoinositide-3-kinase (PI3K) and 
subsequent actin cytoskeleton rearrangement via RhoA and Cdc42 Rho GTPases162,163. Activation of EphA2 
was suggested to enhance pre-existing FAK/Src/PI3K phosphorylation, resulting in recruitment and 
activation of various signaling adaptors such as c-cbl and myosinIIA, c-cbl-dependent polyubiquitination of 
EphA2 and subsequent clathrin-mediated endocytosis144. In HMVEC-d, analog, gB-integrin and EphA2-
dependent signaling cascades were described to initiate translocation of multimolecular signaling 
complexes to lipid rafts. Here, EphA2 knockout was shown to have no effect on FAK phosphorylation145. 
Lipid raft localization and induction of macropinocytosis was determined to rely on c-cbl-mediated 
monoubiqitination of integrins and interaction with myosinIIA164,165. Disruption of macropinocytosis 
resulted in clathrin-mediated endocytosis, which led to non-productive infection in HMVEC-d. Additional 
proposed co-regulatory factors and adaptors, such as CIB1, Crk, p130Cas, Hrs, AP-2 and Eps-15144,146,147,165 
are not shown for clarity. Of note, other studies did not detect a role of α3β1 in KSHV infection but 
demonstrated the relevance of the specific interaction of αVβ3 with the gB RDG motif for KSHV infection of 
epithelial cells47,140,166,167 and a recent study described integrin α3β1 αVβ3 and αVβ5 independent infection 
of two cancer cell lines (SLK/Caki-1 and HeLa)143. How these – potentially cell type-specific – mechanistic 
differences are regulated remains to be determined.  
 
Another cellular host factor described to be involved in KSHV entry is the glutamate/cysteine 
exchange transporter xCT168, one of the variable light chains composing the heteromeric CD98/xCT 
complex. CD98, the common heavy chain, regulates amino acid transport169 and is involved in 
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integrin activation and signaling170–172. Correspondingly, the presence of xCT/CD98 has been 
demonstrated in multimolecular complexes with integrins during KSHV infection141,173. However, a 
viral interaction partner for the xCT/CD98 complex has yet to be identified.  
 
I.4.2.1. Spotlight - The Eph receptor tyrosine kinase family 
 
With 14 members, Eph receptors comprise the largest known family of receptor tyrosine 
kinases in the human proteome. The family is subdivided in nine A-type and five B-type Ephs, which 
preferentially interact with the five glycosylphosphatidylinositol (GPI)-anchored ephrin A-ligands or 
the three transmembrane ephrin B-ligands, respectively, at sites of cell-cell contact174,175. Eph-ephrin 
complexes are unique in their bidirectional signaling capacity, in which Eph kinase activity induces 
signaling cascades in the receptor-expressing cells176,177, while reverse signaling in the ligand-
expressing cells depends on non-receptor tyrosine kinases178. Rearrangement of the actin 
cytoskeleton as well as activation of integrins and intracellular adhesion molecules induced by Eph 
signaling are implicated in a wide range of cellular processes, including cell morphology, adhesion, 
migration and invasion177,179. Furthermore, Eph-ephrin signaling is involved in many aspects of 
embryogenesis, such as segmentation, neural crest cell migration, angiogenesis, and axon 
guidance180–182.  
Additionally, cumulative evidence links Eph expression to cancer development and 
progression. For instance, EphA1, the first described Eph receptor was identified in a screen for new 
oncogenic tyrosine kinases183. Similarly, EphA2, the high-affinity receptor for the KSHV gH/gL complex 
was initially identified in a cDNA library of a cervical cancer cell line184. Since then, EphA2 
overexpression was reported in a wide range of solid tumors including cancers of the reproductive 
system (e.g. breast, ovary, cervical, prostate cancers), the gastrointestinal system (e.g. esophageal, 
gastric, colorectal cancers) and cancers in additional organs (e.g. lung, pancreas and renal cancer, 
glioblastoma, melanoma and neck squamous cell carcinomas)185–191. High expression of EphA2 is 
generally correlated with more aggressive cancer phenotypes and poor prognosis192–196 and was 
found to promote metastasis, angiogenesis, and resistance development to therapeutical approaches 
directed against e.g. the ErbB tyrosine kinase197–204. However, in recent years the dogma of EphA2 as 
mere oncogene was challenged. The current literature supports a role of the canonical ephrin-
dependent activation of EphA2 tyrosine kinase activity in tumor suppression, while the non-canonical 
EphA2 tyrosine kinase-independent phosphorylation on Ser897, mediated by Akt kinase, activated by 
several growth factors (e.g. epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), 
hepatocyte growth factor/scatter factor (HGF/SF), and platelet-derived growth factor (PDGF)) has 
pro-oncogenic functions205–209. 
 





Figure 6 Eph receptor domain structure, canonical and non-canonical signaling pathways. Ligand-
induced Eph receptor forward signaling is characterized by autophosphorylation of tyrosine residues (blue 
P), clustering into hetero- or homomeric complexes and recruitment of adaptor and effector proteins. 
Receptor binding induces reverse signaling events through non-receptor tyrosine kinases in GPI-anchored 
A-type ephrin and transmembrane B-type ephrin expressing cells
175–177
. The canonical pathway of 
ephrinA1-ligand dependent EphA2 tyrosine phosphorylation and activation confers tumor suppressor 
activity of EphA2 by 1) inhibition of the PI3K/Akt pathway
205,210,211
, 2) reduction of Integrin- or Growth 
Factor (GF) Receptor-dependent phosphorylation of focal adhesion kinase (FAK) through the Src 
homology region 2 domain-containing phosphatase 2 (SHP2) which leads to an inhibition of the FAK/Src 
pathway
212–214
 and 3) suppression of the ADP-ribosylation factor 6 (Arf6) though interaction with the 
adaptor protein Nck1 and the G protein-coupled receptor kinase-interacting protein 1 (Git1)
215
. EphrinA1-





 the MAP/ERK kinase signaling cascade leading to anti- or pro-oncogenic cellular responses. 
One study proposes a pro-oncogenic role of ephrinA1-EphA2 interaction through activation of 
Phosphoinositide-3-kinase (PI3K) and Ras-related C3 botulinum toxin substrate 1 (Rac1)
207
. In general, 
discrepancies between ephrinA1-EphA2 induced signaling observed in various studies could e.g. be due to 
cell type-specific signaling, effects of the interaction of ephrinA1 with additional A-type Eph receptors or 
as recently proposed due to differences in the spatial organization of EphA2 receptor and ephrinA1 
ligands
218,219
. The non-canonical, ligand-independent pathway relies on phosphorylation of serine 897 
(Ser897, red P) through the Akt kinase upon induction of growth factor (GF) receptor signaling
205–209
. 
Upon KSHV infection, androgen receptor-mediated activation of the p90 ribosomal S6 kinase1 (RSK1) and 
subsequent EphA2 phosphorylation at Ser897 was shown to regulate efficient KSHV endocytosis
148
. 
Pathways/components involved in tumor suppression are depicted in shades of blue; 
Pathways/components involved in tumor promotion or depicted in shades of orange. 
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Supporting this notion, the ephrinA1-dependent activation of EphA2 can inhibit migration and 
proliferation in vascular endothelial cells
220
 and attenuate growth factor-induced activation of the 
Ras/ERK cascade to reduce migration, invasion, proliferation and survival of cancer cells
206,216
. 
Furthermore, the ephrin-dependent inactivation/inhibition of e.g. the focal adhesion kinase (FAK) 
and Akt pathways regulate motility, viability, and proliferation of cancer cells
205,210,212,213
. In solid 
tumors, such as breast cancer, glioblastoma and hepatocellular carcinoma overexpression of EphA2 
and ephrinA1 was shown to be mutually exclusive in many cases 
206,221–225
, which further supports a 
role of the canonical signaling pathway in tumor suppression (detailed in Figure 6).  
Notably, the pathological functions of EphA2 are not restricted to oncology. In addition to 
KSHV, EphA2 has been described as host factors for a wide range of pathogen species, including 
viruses (i.e. EBV
226,227
, hepatitis C virus
228
), bacteria (i.e. Chlamydia trachomatis
229
), fungal pathogens 
(Cryptococcus neoformans
230
), and parasites (i.e. plasmodium
231
). However, the reasons for the 
apparent preference of different pathogens for EphA2 as a host factor remain to be elucidated. 
 
I.5 Keeping it in the family - Simian model systems of KSHV 
 
Analyses of the complete KSHV life cycle as well as KSHV propagation and dissemination in the 
host organism are limited by the lack of traditional permissive lytic systems that allow us to study a 
full herpesviral life cycle, and established permissive animal models, which support a systemic KSHV 
infection. While one study demonstrated the experimental infection of common marmosets 
(Callithrix jacchus) with KSHV
232
, follow-up studies refining this model system are still lacking. 
Therefore, studying simian homologs of KSHV and their associated malignancies in non-human 
primate models provides important approaches for understanding KSHV biology as well as the role of 
γ-herpesviruses in tumorigenesis in general.  
Several studies have addressed the suitability of RRV infection in rhesus macaques as model 
for the development of AIDS-related KS after experimental co-infection with simian 
immunodeficiency virus (SIV). Up to date, two cloned RRV isolates, namely RRV 26-95
233
 and RRV 
17577
234
, that represent the two major RRV sequence groups based on glycoprotein primary 
sequence
235
, are available. Analogous to KSHV-associated lymphoproliferative disorders, RRV 
infection was correlated with lymphomagenesis in models of simian (human) immunodeficiency virus 
(SIV/SHIV) infected rhesus macaques
236,237
. Similarly, co-infection with SIV led to B cell lymphoma 
development in animals experimentally infected with RRV 17577
238,239
. Even though there is no clear 
association of RRV with solid malignancies, RRV, in addition to retroperitoneal fibromatosis 
herpesvirus (RFHV), has been identified in retroperitoneal fibromatosis tissue
237,239,240
. Since the first 
use of RRV as model for AIDS-associated KSHV-malignancies in SIV co-infected rhesus macaques
238,241
, 
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RRV has found applications not only in studies to unravel rhadinovirus disease development in the 
context of HIV/SIV infection237,239, but has also shown promise as vaccine vector for HIV/SIV242–245 and 
as viral vector for e.g. antibody delivery246. 
Studying parallels and differences between KSHV and its non-human primate homologs in cell 
culture settings can help decipher the complex entry process of KSHV by e.g. highlighting 
fundamental, conserved mechanisms and host factors. Up to date, all obtained RRV glycoprotein 
sequences can be classified in one of two distinct sequence clades that are characterized by stark 
differences in the extracellular domain of gH as well as gL, while other glycoproteins, including gM 
and gN show only minor variation235. Despite of these differences in the primary sequences, 
interaction of the gH/gL complex with members of the Eph family – which parallels the KSHV 
gH/gL- Eph interaction – is conserved between RRV 26-95 and RRV 17577 as the prototypic members 
of both clades. However, differences do exist between both RRV isolates as well as between RRV and 
KSHV regarding the affinities for different Eph receptors, most notably seen in the preference of 
KSHV for A-type and of RRV for B-type Ephs247. Nevertheless, this separation is not stringent as KSHV 
gH/gL also co-immunoprecipitated EphB1 in mass spectrometry experiments and both RRV isolates 
were shown to interact with EphA4, EphA5 and EphA7 in the same setting247. Two of the RRV-
interacting A-type Ephs, namely EphA4 and EphA5 where described as functional KSHV receptors in 
overexpression systems143,150,247 hinting to a possibly congruent role for Eph receptors in RRV and 
KSHV – and in extension rhadinovirus – entry. Interestingly, while established B cell lines are 
generally refractory to KSHV cell-free infection, certain B cell lines, such as BJAB cells support 
cell-free RRV infection. Analyzing parallels and differences in the infection of these model cell lines 

















In spite of advances in unraveling the rhadinoviral entry process, the complex mechanism is 
still not completely understood. While Eph receptors were identified as key players in KSHV and RRV 
infection, and the interaction domain on the cellular Eph receptor has been described
149
, the distinct 
viral sequence motif or domain that mediates this interaction has not yet been identified. The 
generation of targeted intervention strategies and virus mutants, e.g. as attenuated vaccine vectors, 
relies on detailed information on the structural and amino acid level. The identification of these viral 
interaction motifs therefore not only furthers basic research on rhadinoviral entry but could also 
provide starting points for the development of KSHV prevention and treatment strategies.  
Furthermore, even though the role of Eph receptors in the KSHV entry of adherent cell lines 
has been the focus of several studies, reports on the usage of specific Eph receptors for the infection 
of B cells are still sparse. As B cells represent the major reservoir for latent KSHV and RRV infection in 
vivo and give rise to two KSHV-associated malignancies, elucidating the process of B cell infection is 
important for the understanding of KSHV biology and pathogenesis.  
In general, blocking of one individual receptor interaction (e.g. the gH/gL-Eph interaction) does 
not completely abrogate the infection of KSHV and RRV on the majority of analyzed cell types which 
implies the usage of alternative, redundant entry receptors for rhadinoviral infection. A recent report 
demonstrated the strict necessity of gH for KSHV infection of fibroblasts, epithelial and endothelial 
cells
248
 which could suggest the existence of at least one additional gH-interacting host factor. 
Therefore, the aims of this study were as follows: 
 
Aim1: Characterize the Eph interaction motif on the rhadinoviral gH/gL complex and evaluate the cell 
type-specific contribution of the Eph interaction to KSHV/ RRV infection 
 
Aim2: Identify Eph receptors that play a role in the infection of B cells, using the BJAB model cell line 
 
Aim3: Identify and characterize putative additional rhadinoviral receptors that interact with gH or the 
gH/gL complex 
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As detailed above, different aspects of the rhadinoviral interaction with members of the Eph receptor 
family still warrant further analysis. Therefore, the first part of my thesis addressed the questions: 
 
1) Whether an essential sequence motif on gH/gL confers KSHV/ RRV interaction with Eph 
family receptors  
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2) Whether the functional conservation of the gH/gL-Eph interaction displayed by KSHV and 
RRV relies on a similar conservation on primary sequence or structural level  
3) Whether the Eph interaction is essential for infectivity or tropism on distinct cell types, which 
can be determined by mutation of the Eph-interacting region on gH/gL 
 
To identify regions in KSHV gH/gL that specifically mediate the interaction with the high-affinity KSHV 
receptor EphA2, we performed co-immunoprecipitation experiments of a series of KSHV/ RRV 
glycoprotein H and L chimeras with full-length EphA2. This approach indicated the N-terminal regions 
of gH as well as gL as crucial for the interaction with EphA2. Further analyses demonstrated that 
mutation of two amino acids in a five amino acid motif in domain I of KSHV and RRV gH to alanine 
(Glu-Leu-Glu-Phe-Asn [ELEFN  ELAAN]) is sufficient to abrogate the KSHV gH/gL-EphA2 and the RRV 
gH/gL-EphB3 interaction, respectively. Interestingly, although KSHV and the two RRV isolates 26-95 
and 17577 display distinct, divergent affinities for members of the Eph receptor family, this motif is 
fully conserved between all three virus isolates. 
In depth analysis of KSHV and RRV 26-95 virus strains mutated in the described ELEFN motif (KSHV 
gH-ELAAN, RRV gH-AELAAN) confirmed the essential nature of this motif for Eph-interaction using 
soluble decoy receptors and ligands in inhibition experiments and demonstrated the versatility of 
this mutant virus system for the analysis of Eph receptor contribution to rhadinovirus entry. In 
contrast to the single cycle KSHV stock production, RRV stock production requires multi-step lytic 
replication. We therefore included an additional mutation in RRV gH which further disrupts the 
gH/gL-Eph interaction to avoid functional reversion. An RRV control mutant, negative for gL, which is 
equally essential for the Eph-interaction as gH confirmed findings obtained with RRV gH-AELAAN. 
Analysis of virus attachment as well as specific infectivity on different adherent cell types showed, 
that while KSHV and RRV attachment was not significantly altered by mutation of the Eph-interaction 
motif or deletion of RRV gL, the specific infectivity of Eph de-targeted mutants was reduced on all 
analyzed cell types when compared to wild-type virus infection normalized to viral particles. For both 
viruses, the effects ranged from approx. 5-fold to at least 9-fold, or even 20-fold (for RRV on 
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S1 Fig. Effect of single point mutations in the N-terminal domain of gH on gH/gL stability and 
complexation as well as gH and gL incorporation in the virus particles. A Effects of point mutations on 
the stability of KSHV gH/gL complexes in the absence of recombinant Eph receptors. V5-tagged KSHV gH 
mutants were co-expressed with Flag-tagged KSHV gL. gH-V5/gL-Flag complexes were 
immunoprecipitated using monoclonal antibody to the V5-tag and precipitates were analyzed by Western 
blot. KSHV gH/RRV gL and KSHV gH alone serve as negative control. B Effects of point mutations on the 
stability of RRV gH/gL complexes in the absence of recombinant Eph receptors. V5-tagged RRV gH 
mutants were co-expressed with Flag-tagged RRV gL. gH-V5/gL-Flag complexes were immunoprecipitated 
and analyzed as in A. KSHV gH/RRV gL and RRV gH alone serve as negative control. C Point mutations in 
the E-L-E-F-N motif of KSHV and RRV gH do not influence stability of gH alone or of the gH/gL complex. V5-
tagged KSHV gH wt, gH E52AF53A (gH-ELAAN), RRV gH wt and gH V51AE54AF55A (gH-AELAAN) were 
either expressed alone or co-expressed with Flag-tagged KSHV/RRV gL. gH-V5 and gH-V5/gL-Flag 
complexes were immunoprecipitated and analyzed as in A. D Double mutation E52AF53A in KSHV gH does 
not influence the incorporation of gH into the virus particle. KSHV wt, and gH-ELAAN virus preparations 
were analyzed by Western Blot. K8.1 was used as loading control. K8.1 runs in a diffuse molecular weight 
pattern due to its complex O-glycosylation. E Triple mutation V51AE54AF55A in RRV gH (gH-AELAAN) does 
not influence the incorporation of gH and gL into the virus particle. RRV wt, gH-AELAAN and RRV ΔgL virus 
preparations were analyzed by Western Blot. gB was used as loading control. Abbreviations: IP: 





S2 Fig. Specific infectivity of Eph-binding-negative RRV and KSHV mutants. A-B Eph-binding-negative 
RRV and KSHV mutants exhibit a reduced specific infection on epithelial cells. Target cells were infected 
with KSHV wt and gH-ELAAN (A) or RRV wt, gH-AELAAN and ΔgL (B) at the indicated virus concentrations. 
GFP (KSHV) or YFP (RRV) expression as indicator of infection was measured by flow cytometry (triplicates, 
error bars indicate sd). C-D Eph-binding-negative RRV and KSHV mutants exhibit a reduced specific 
infection assayed by mean fluorescence intensity (MFI) of the respective reporter gene. Target cells were 
infected with KSHV wt and gH-ELAAN (C) or RRV wt, gH-AELAAN and ΔgL (D) at the indicated virus 
concentrations. GFP (KSHV) or YFP (RRV) MFI as indicator of infection was measured by flow cytometry 







S3 Fig. Contribution of the gH/gL-Eph interaction to KSHV infection of endothelial cells and fibroblasts. 
A-B Comparison of KSHV wt with KSHV gH-ELAAN infection based on GFP reporter gene-positive cells on 
LEC (A) or HUVEC (B) and HFF. HFF and LEC or HUVEC were infected with the same inocula of the 
respective virus stock, and the percentage of reporter gene-positive cells as determined by flow 
cytometry for each dilution was plotted. C Micrograph of HFF and LEC infected with the same inocula of 
wt and Eph-binding-negative KSHV. D-E Comparison of KSHV wt and KSHV gH-ELAAN infection based on 
MFI on LEC (D) or HUVEC (E) and HFF performed as in (A-B). 
 
S4 Table  List of accession numbers, primers, and antibodies used in this study.
A) NCBI database sequence accession numbers
Gene accession number 
human EphA2 NM_004431 
EphB3 BC052968 
viral KSHV gH GQ994935.1
KSHV gL GQ994935.1
RRV 26-95 gH AF210726.1
RRV 26-95 gL AF210726.1
name sequence
BAC mutagenesis KSHV gH-ELAAN forward         





Sequencing PCR KSHV gH-ELAANseq forward 5'-GCCTGGCACACAAGGAGGAA-3'
KSHV gH-ELAANseq reverse 5'-TCGGCACCTCGCACGTATAG-3'
RRV gH-AELAANseq forward 5'-TCCAGATTGACTCATCGGTTTC-3'
RRV gH-AELAANseq reverse 5'-TCCAATCGGCTGTCATAATACC-3'






genomic CCR5 primer1 5'-CCCAGTGGGACTTTGGAAATA-3'
(human/ rhesus) primer2 5'-CGATTGTCAGGAGGATGATGAA-3'
probe 5'-/56-FAM/TGTGTCAAC/ZEN/TCTTGACAGGGCTCT/3IABkFQ/-3'
C) gH and gL constructs and primers
KSHV amino acids RRV amino acids
chimera1 DI-DIV 1-700 TM 698-end
chimera2 DI-DIV 1-601 DIV-TM 599-end
chimera3 DI-DIII 1-504 DIII-TM 502-end
chimera4 DI-DIII 1-400 DIII-TM 401-end
chimera5 DI-DII 1-301 DII-TM 301-end
chimera6 DI-DII 1-199 DII-TM 199-end
chimera7 DI-DII 1-94 DII-TM 99-end
KSHV fragment forward RRV fragment reverse
chimera1-7 5'-AAGGATCCACCATGCAGGGTCTAGCCTTCTTG-3' 5'-CTAGAAGGCACAGTCGAGGC-3'









KSHV gL∆135-164 5'-AGGGAAAAGACTACAAGGACGACGATG-3' 5-TTATTATAATTATGTTTACGTTGTG-3'
Western Blot Target Clone/ Number Species concentration Manufacturer
primary antibodies V5 tag/ PK tag SV5-Pk1 mouse 1:1000 Bio-Rad
c-myc 9E10 mouse 1:1000 Santa Cruz Bio
c-myc C3956 rabbit 1:1000 Sigma-Aldrich
DYKDDDDK tag (Flag) 6F7 rat 1:1000 Serotec
DYKDDDDK tag (Flag) D6W58 rabbit 1:1000 Cell Signaling Technology
HA tag HA-7 mouse 1:1000 Sigma-Aldrich
RRV gH-2 custom rabbit 1:500 GenScript
RRV gL-1 custom rabbit 1:500 GenScript
RRV gB 3H8.1 mouse 1:1000 Scott W. Wong (Vaccine and Gene Therapy Institute, 
Oregon Health & Science University) 
KSHV gH-1 custom rabbit 1:500 GenScript
KSHV K8.1 Bs555 mouse 1:1000 Lang et al., J Clin Microbiol. 2002
secondary 
antibodies (HRP) mouse donkey 1:20 000 Jackson ImmunoResearch
rat chicken 1:10 000 Santa Cruz Bio
rabbit donkey 1:20 000 Jackson ImmunoResearch





















Correction of RRV-YFP-∆gL sequence 
Posted by ahahn101 on 10 Oct 2019 at 17:44 GMT  
As a result of a sequencing oversight that we recently noticed after depositing our sequences in 
GenBank, the RRV-YFP-ΔgL virus described in our publication that is negative for gL expression in 
virus particles contains not only the indicated 128 base pair deletion from position 80 to 207 of the 
coding sequence but also a single base pair deletion at position 66. The corrected sequence of RRV-
YFP-ΔgL has been deposited under accession number MN488838. The conclusions of our publication 
are not affected. 
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III.2 Publication 2: EphA7 functions as Receptor on BJAB Cells for Cell-to-Cell 
Transmission of the Kaposi's Sarcoma-Associated Herpesvirus (KSHV) and for 
Cell-Free Infection by the Related Rhesus Monkey Rhadinovirus (RRV) 
 
Journal of Virology, Published: July 17, 2019 
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A longstanding problem in the KSHV field lies in the inability of KSHV to infect B cell cultures as cell-
free virus in vitro. Even though this refractoriness to cell-free infection can be partially overcome by a 
co-culture infection approach64, data on the receptor usage of KSHV for B cell infection is still sparse. 
We therefore aimed to analyze: 
 
1) Which Eph receptors mediate rhadinovirus entry into B cells, using BJAB cells as a model 
cell line 
2) The contribution of identified Eph receptors to cell-to-cell transmission of KSHV and cell-
free infection of RRV on BJAB B cells 
3) If Eph receptor expression in BJAB cells is paralleled in KSHV-associated malignancies, 
using KSHV-PEL cell lines as a model system 
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To identify Eph family members that could mediate KSHV and RRV infection of BJAB cells, LC-MS/MS 
had been performed after precipitation of BJAB cell lysate with the gH/gL complexes of KSHV, RRV 
26-95 and RRV 17577 by Alexander Hahn in the laboratory of Ron Desrosiers. The identified 
interaction of RRV and KSHV with EphA7 as well as of KSHV with EphA5 fitted well with published Eph 
mRNA expression profiles in BJAB cells and was verified by further immunoprecipitation experiments. 
In CRISPR/Cas9 knockout experiments, abrogation of the EphA7 expression in BJAB cells led to an 
approx. 75% reduction of KSHV cell-to-cell transmission and 95% reduction of RRV cell-free infection, 
respectively. Similarly, knockdown of EphA5 reduced KSHV infection by approx. 60% and RRV 
infection by approx. 40%.  
 
Rescue of KSHV and RRV infection upon lentiviral reconstitution of EphA7 expression in monoclonal 
EphA7 knockout cells confirmed the dependence of both viruses on EphA7 for entry into BJAB cells 
and excluded a contribution of CRISPR/Cas9 off-target effects.  
Interestingly, one of three analyzed PEL cell lines expressed EphA7 to similar levels as BJAB cells in 
our experimental setup, while the remaining two PEL cell lines expressed high levels of EphA2 but 
were negative for EphA7. This could hint to a role of KSHV-interacting Eph receptors in the 
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The inability to completely abrogate KSHV and RRV infection by disruption of the interaction with 
described cellular host factors suggests the existence of additional, yet unidentified cellular receptors 
that play a role in rhadinoviral entry. Therefore, in this part of my thesis, I aimed to determine: 
 
1) Whether we can identify additional receptors that interact with the rhadinoviral gH/gL 
complex or gH alone 
2) If so, which domains or regions on gH mediate the interaction with identified receptors 
3) Whether interactions with additional putative gH receptors are cell type-specific/ shape 
the rhadinoviral tropism 
 
Using affinity enrichment followed by mass spectrometry, the family of Plexin domain containing 
proteins (Plxdc1/2) had been identified as novel interaction partners for the gH/gL complex of RRV, 
but not KSHV by Alexander Hahn in the laboratory of Ron Desrosiers. Using immunoprecipitation 
assays we characterized the binding specificities of the gH/gL complexes of isolates from the two 
defined RRV sequence groups235. While RRV isolate 17577 gH selectively binds to Plxdc1 in the 
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presence of gL, RRV 26-95 gH interacts with both Plxdc1 and Plxdc2, independently of gL. Blocking 
assays with soluble Plxdc2 decoy receptor demonstrated the functionality of the gH-Plxdc2 
interaction on the virion. Ectopic overexpression of Plxdc1/2 further confirmed the importance of 
this interaction in the context of infection and verified Plxdc1/2 as a functional receptor for RRV 
26-95. Furthermore, we could establish the independence of the Eph receptor and Plxdc receptor 
interaction by co-immunoprecipitation of gH/gL-Plxdc1/2-EphB3 complexes and blocking assays with 
soluble Plxdc2-Fc and EphB3-Fc.  
We mapped the Plxdc-interaction motif to a seven/ six amino acid stretch on gH of RRV isolate 
26-95/ isolate 17577 and characterized the amino acids which are crucial for the interaction in more 
detail. Deletion of this motif is sufficient to abrogate RRV 26-95 and RRV 17577 gH interaction with 
Plxdcs and to de-target RRV 26-95 from Plxdc receptors in the context of infection.  
We used RRV 26-95 recombinants, deleted in the seven amino Plxdc-interaction motif or mutated in 
the previously described Eph interaction motif (see Publication 1) to determine the contribution of 
the gH-Plxdc interaction to attachment and the cell line-specific infectivity of RRV 26-95. While RRV 
seems to be able to use both receptor families for the infection of adherent cell lines, we identified 
B cell lines which exhibit a preferential infection via interaction with either Plxdc receptors (namely 
MFB5487) or Eph receptors (Raji, MMB1845). Interestingly, even though Plxdc1 or Plxdc2 enhanced 
RRV 26-95 infection to similar levels upon ectopic overexpression, only Plxdc1 overexpression 
resulted in differences in the attachment efficiency of RRV 26-95 which could hint at differing 
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ABSTRACT  10 
The rhesus monkey rhadinovirus (RRV), a γ2-herpesvirus of rhesus macaques, shares many biological 11 
features with the human pathogenic Kaposi’s sarcoma-associated herpesvirus (KSHV). Both viruses, 12 
as well as the more distantly related Epstein-Barr virus, engage cellular receptors from the Eph family 13 
of receptor tyrosine kinases (Ephs). However, the importance of the Eph interaction for RRV entry 14 
varies between cell types suggesting the existence of Eph-independent entry pathways. We 15 
therefore aimed to identify additional cellular receptors for RRV by affinity enrichment and mass 16 
spectrometry. We identified an additional receptor family, the Plexin domain containing proteins 1 17 
and 2 (Plxdc1/2) that bind the RRV gH/gL glycoprotein complex. In vitro, blocking assays with soluble 18 
Plxdc2 decoy receptor reduced RRV infection by approx. 60%, while overexpression of Plxdc1 and 2 19 
dramatically enhanced RRV susceptibility in otherwise marginally permissive Raji cells. While the 20 
Plxdc2 interaction is conserved between two RRV strains, 26-95 and 17577, Plxdc1 specifically 21 
interacts with RRV 26-95 gH. The Plxdc interaction is mediated by a short motif at the N-terminus of 22 
RRV gH that is partially conserved between isolate 26-95 and isolate 17577, but absent in KSHV gH. 23 
Mutation of this motif abrogated the interaction with Plxdc1/2 in in vitro assays and reduced RRV 24 
infection in a cell-type specific manner. Taken together, our findings characterize Plxdc1/2 as novel 25 
interaction partners and entry receptors for RRV and support the concept of the N-terminal domain 26 
of the gammaherpesviral gH/gL complex as a multifunctional receptor-binding domain. 27 
INTRODUCTION 28 
The rhesus monkey rhadinovirus (RRV), a member of the genus γ2-herpesvirus or rhadinovirus, is 29 
closely related to the only human pathogenic member of this genus, the Kaposi’s sarcoma associated 30 
herpesvirus (KSHV) (1, 2). Due to the high similarity in both genome organization and biology RRV is 31 
considered as an animal model virus for KSHV (3) and has been used as such in various in vitro and in 32 
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vivo studies. Two major RRV sequence groups have been identified (4), which are represented by two 33 
cloned isolates, RRV 26-95 (5) and RRV 17577 (6). Analogous to KSHV infection, primary RRV infection 34 
is asymptomatic in healthy hosts and leads to life-long persistence, most likely in the B cell 35 
compartment (7).  KSHV is associated with a solid tumor of endothelial origin, Kaposi’s sarcoma (KS), 36 
and two B cell malignancies, primary effusion lymphoma (PEL) and the plasmablastic variant of 37 
multicentric Castleman’s disease (MCD), most prominently in the context of human 38 
immunodeficiency virus (HIV) infection and in immunocompromised individuals. Similarly, simian 39 
immunodeficiency virus (SIV)-positive rhesus macaques developed B cell lymphomas upon 40 
experimental infection with RRV strain 17577 (8, 9) and several studies correlated RRV infection with 41 
lymphomagenesis in SIV/SHIV-infected animals (10, 11). While RRV is not consistently associated 42 
with solid malignancies, RRV has been identified in retroperitoneal fibromatosis tissue (9, 12), similar 43 
to retroperitoneal fibromatosis herpesvirus (RFHV)(11). Another shared characteristic of KSHV and 44 
RRV is the receptor usage on a range of cell types. Both viruses engage members of the Eph family of 45 
receptor tyrosine kinases (Ephs) through their glycoprotein (g)H/gL complex to facilitate entry into 46 
target cells. While KSHV preferentially interacts with A-type Ephs – specifically EphA2 as the high 47 
affinity receptor (13, 14) – RRV can utilize both A- and B-type Ephs (14) for entry. These interactions 48 
have been characterized on different adherent cells types (6–9) and we could recently show that 49 
both viruses can utilize EphA7 as receptor on BJAB cells (19), a model B lymphocyte line. While for 50 
KSHV, in addition to Eph family receptors, several membrane proteins have been proposed as cellular 51 
receptors for different viral glycoproteins mediating either attachment or entry on a range of target 52 
cells (reviewed in (20)) the receptor usage of RRV is comparatively less well characterized. 53 
Nevertheless, studies using receptor knock-down, receptor- and ligand-mediated blocking, and Eph 54 
de-targeted virus mutants (21) showed that both viruses can infect various cells independently of the 55 
Eph-interaction, which suggests that RRV engages at least one additional entry receptor that can 56 
functionally substitute for the Eph-interaction. This notion is also supported by a recent in vivo study 57 
that demonstrated that an RRV mutant deleted of gL and therefore unable to interact with Eph 58 
receptors still establishes persistent infection in RRV-naïve rhesus macaques upon intravenous 59 
inoculation (22). We therefore aimed to identify additional rhadinovirus receptors that bind the 60 
gH/gL complex or gH and identified Plexin domain containing protein 2 (Plxdc2) as novel interaction 61 
partner of the gH/gL complex of RRV, but not KSHV. The closest homolog to Plxdc2, Plxdc1 was 62 
initially identified as overexpressed in blood vessels of solid human tumors (23), resulting in the 63 
original terminology tumor endothelial marker 7 (TEM7, Plxdc1) and tumor endothelial marker 7 64 
related (TEM7R, Plxdc2) (24). In general, the physiological functions of Plxdc1/2 are not well 65 
understood. Suggestive of a role in development, Plxdc2 has been described as mitogen for neural 66 
progenitor cells (25) and expression of both Plxdc1 and Plxdc2 in the developing nervous system has 67 
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been demonstrated (26, 27). Cortactin, nidogen and the pigment epithelium derived factor (PEDF) 68 
have been described as interactors for Plxdc1 and Plxdc2 (28–30). However, the physiological 69 
relevance of these interactions is not fully understood. In this study we characterize the interaction 70 
of Plxdc1/2 with the gH/gL glycoprotein complex of RRV and establish Plxdcs as novel cellular RRV 71 
entry receptors. 72 
 73 
RESULTS  74 
To identify potential cellular receptors for RRV glycoprotein H, we performed 75 
immunoprecipitation using soluble RRV 26-95 gH, consisting of the extracellular part fused to the Fc 76 
part of human IgG (RRV gH-FcStrep) as bait and 293T whole cell lysate as prey (Fig 1A). Bands present 77 
in the precipitation from 293T whole cell lysate, but not in control precipitation without 293T lysate 78 
were excised and analyzed by LC-MS/MS. The most abundant cell surface protein, identified in four 79 
of the five analyzed regions, was Plxdc2 or TEM7R, a cellular transmembrane protein. As described 80 
above, Plxdc1 or TEM7 is the only homolog of Plxdc2 in humans and rhesus macaques, and was 81 
therefore included in subsequent analyses. Human and rhesus Plxdc1 (ref |NM_020405.5|; ref 82 
|XM_028836436.1|) and Plxdc2 (ref |NM_032812.9|; ref |XM_028826043.1|) are 96.80% and 83 
97.92% identical on the amino sequence level. 84 
Co-immunoprecipitation of V5-tagged expression constructs of gH from KSHV and from the 85 
two RRV isolates 26-95 and 17577, in the presence or absence of the corresponding Flag-tagged gL 86 
proteins with myc-tagged human Plxdc1 or Plxdc2 (hPlxdc1-myc/ hPlxdc2-myc) from transfected 87 
293T cells confirmed the interaction of both RRV gH/gL complexes with Plxdc2 (Fig 1B). Neither KSHV 88 
gH/gL nor RRV 17577 gH/gL interacted detectably with Plxdc1-myc, while RRV 26-95 prominently 89 
bound both Plxdc1 and Plxdc2 in the presence and absence of gL.  90 
To evaluate the effect of Plxdc-binding to RRV gH on the interaction with EphB3, the high-91 
affinity Eph family receptor for RRV gH/gL (14), we used soluble human Plxdc1 or Plxdc2, consisting 92 
of the extracellular part of Plxdc1 or Plxdc2 fused to the Fc part of human IgG followed by a 93 
TwinStrep tag (hPlxdc1-FcStrep/ hPlxdc2-FcStrep) in immunoprecipitation experiments. Co-94 
immunoprecipitation of hPlxdc1-FcStrep/ hPlxdc2-FcStrep with the gH-V5/gL-Flag complexes of RRV 95 
isolates 26-95 and 17577 in the presence or absence of myc-tagged EphB3 from transfected 293T 96 
cells demonstrated the existence of a quaternary complex, indicating the ability of RRV gH/gL to 97 
interact with members of both receptor families simultaneously (Fig 1C).  98 
While interaction in transfected cell lysates is strongly suggestive of a functional interaction, 99 
the biologically relevant interaction for the entry process would occur with virion gH/gL. To evaluate 100 
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the functionality of the gH/gL – Plxdc interaction on virus particles both for wildtype RRV and an Eph-101 
binding-negative RRV mutant, we utilized RRV-YFP, an RRV 26-95 strain engineered for constitutive 102 
YFP expression upon infection, and RRV-YFP gH-AELAAN, an Eph-binding-negative RRV-YFP mutant 103 
that we had previously described (Fig 2A) (21). To analyze the impact of competition with soluble 104 
Plxdc decoy receptor, RRV-YFP and RRV-YFP gH-AELAAN preparations were incubated with a 105 
concentration series of soluble hPlxdc2-FcStrep or an FcStrep control prior to infection of HaCaT cells 106 
(Fig 2B). According to RNA-Seq data of 36 cell lines (Courtesy of Human Protein Atlas, 107 
www.proteinatlas.org, (31)), HaCaT cells exhibit the highest cell-line specific expression of Plxdc2 108 
among the analyzed non-cancer cell lines and were therefore chosen for further analyses. Soluble 109 
Plxdc2-FcStrep inhibited RRV-YFP wt infection up to approx. 60% in a dose dependent manner when 110 
compared to FcStrep alone. Likewise, preincubation of RRV-YFP gH-AELAAN with hPlxdc2-FcStrep 111 
reduced infection by approx. 65%. RRV wt and RRV gH-AELAAN infection was normalized to approx. 112 
MOI 0.2. Inhibition of the gH/gL-Eph interaction, which served as control, lead to an approx. 50% 113 
reduction of RRV wt infection at a concentration of 10nM hEphB3-Fc while 100nM of soluble 114 
hPlxdc2-FcStrep exhibited a similar blocking efficiency. Preincubation with both hEphB3-Fc and 115 
hPlxdc2-FcStrep further reduced RRV wt infection on HaCaT cells, when compared to preincubation 116 
with either hEphB3-Fc or hPlxdc2-FcStrep alone (Fig 2C).  While preincubation with EphB3-Fc did not 117 
reduce RRV gH-AELAAN infection, preincubation with either hPlxdc2-FcStrep or a combination of 118 
hPlxdc2-FcStrep and hEphB3-Fc reduced infection by approx. 50% as observed for RRV wt infection 119 
(Fig 2C). Infection of SLK cells and rhesus monkey fibroblasts was also slightly decreased by 120 
preincubation of the viral inoculum with hPlxdc2-FcStrep, infection of SLK by RRV-YFP wt to 63.5% ± 121 
3.7% and infection of RF by RRV-YFP wt to 73.9% ± 11.3% relative to preincubation with FcStrep as 122 
control. However, this effect was less pronounced than on HaCaT and less pronounced than the 123 
effect of hPlxdc2-FcStrep on RRV gH-AELAAN infection of the same cell types (Fig 2D). Taken 124 
together, the immunoprecipitation and blocking experiments confirm the independence of the 125 
gH-Plxdc interaction of the previously described Eph-interaction motif (21) and EphB3-binding. 126 
To establish receptor function, we performed gain-of-function experiments using ectopic 127 
Plxdc1/2 overexpression. Raji cells were transduced with lentiviruses encoding TwinStrep-tagged 128 
human Plxdc1/2 constructs (hPlxdc1-Strep/ hPlxdc2-Strep). The EBV-positive, human lymphoblast 129 
cell line only allows for low-level RRV 26-95 infection even with amounts of input virus corresponding 130 
to high MOI on adherent cells like SLK, HaCaT or RF. Therefore, changes in susceptibility to infection, 131 
mediated by Plxdc1/2 overexpression should be readily detectable and allow for a clear 132 
differentiation of the contribution of Plxdc1/2 to RRV infection over the very low intrinsic 133 
susceptibility to infection. Indeed, ectopic expression of hPlxdc1/2-Strep increased RRV-YFP wt and 134 
RRV-YFP gH-AELAAN infection 40 to 60-fold from approx. 0.5% basal infection dependent on the 135 
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expression plasmid and RRV strain (Fig 2E, G). However, we did not observe pronounced differences 136 
in effects mediated by hPlxdc1-Strep or hPlxdc2-Strep, indicating no clear Plxdc receptor preference 137 
of RRV 26-95. 138 
In a next step we characterized the Plxdc binding motif on RRV gH. As the RRV 17577 gH-139 
Plxdc2 interaction depends on gL whereas the RRV 26-95 gH-Plxdc2 interaction does not, we focused 140 
on the N-terminal domain I of gH which, in analogy to EBV gH/gL (32), most likely constitutes the gL-141 
binding interface. The differences in the Plxdc interaction of RRV isolates 26-95 and 17577 as well as 142 
the lack of Plxdc – KSHV gH/gL interaction suggested a motif that is only partially conserved between 143 
the RRV isolates but missing in KSHV. Using sequence comparisons (Fig 3A) we identified a putative 144 
interaction motif spanning 7 or 6 amino acid motif in the N-terminal region of RRV 26-95 gH and RRV 145 
17577 gH, respectively, that is not conserved in KSHV gH. The motif is located close to the Eph-146 
interaction motif we described previously, facing in the opposite direction in a homology model of 147 
the RRV 26-95 gH/gL complex based on the EBV gH/gL crystal structure (3PHF) (Fig 3B). Deletion of 148 
this motif completely abrogated the gH/gL interaction with Plxdcs of both RRV 26-95 (Fig 3C) and RRV 149 
17577 (Fig 3D). To further characterize the contribution of individual residues in the ‘Tyr(Y)-Glu(E)-150 
Tyr(Y)-Asn(N)-Glu(E)-Glu(E)-Lys(K)’ (RRV 26-95) motif we performed single amino acid substitutions 151 
to alanine. The ability of mutant RRV 26-95 gH-V5 to bind myc-tagged Plxdc1/2 of human (hPlxdc1/2-152 
myc) (Fig 3E) or rhesus macaque origin (mmPlxdc1/2-myc) (Fig 3F) was analyzed by 153 
immunoprecipitation of gH via the V5-tag and Western blot. While several single amino acid 154 
substitutions decreased the interaction of RRV gH with Plxdcs to some degree, residues Tyr23 and 155 
Glu25 that are conserved in isolates 26-95 and 17577 appear to be critical for the interaction of gH 156 
with human and rhesus macaque Plxdc1 and Plxdc2. Furthermore, substitution of glutamate with 157 
alanine at position 22, which is not conserved between isolates 26-95 and 17577, had a pronounced, 158 
albeit slightly weaker effect on the gH-Plxdc1/2 interaction (Fig 3E, F). 159 
To further analyze the contribution of the gH/gL – Plxdc interaction in the context of infection 160 
we constructed virus mutants deleted in the seven amino acid interaction motif in the background of 161 
RRV-YFP 26-95 wildtype (RRV gH∆21-27), and in the background of an RRV-YFP 26-95 strain mutated 162 
in the Eph-interaction motif described previously by our group (RRV gH-AELAAN, RRV gH∆21-27-163 
AELAAN) using a two-step, lambda red-mediated recombination system (33) (Fig 4A). Blocking 164 
experiments using soluble hPlxdc2-FcStrep decoy receptor on HaCaT cells confirmed that deletion of 165 
the seven amino acid motif was sufficient to abrogate the gH-Plxdc2 interaction on viral particles (Fig 166 
4B). While infection of RRV wt and RRV gH-AELAAN was inhibited by approx. 60% to 70% 167 
respectively, infection of RRV gH∆21-27 and RRV gH∆21-27-AELAAN was not affected even by high 168 
concentrations of soluble hPlxdc2-FcStrep (Fig 4B). All infections were carried out at approx. MOI 169 
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0.05. Analogously, the Eph- or Plxdc-receptor-binding-negative RRV mutants were no longer inhibited 170 
by preincubation with the respective soluble receptor (hEphB3-Fc or hPlxdc2-FcStrep) in single or 171 
double inhibition experiments on HaCaT cells (Fig 4C). The receptor-specificity conveyed by the 172 
respective interaction motif was further analyzed in lentiviral vector-mediated Plxdc1/2-Strep 173 
overexpression experiments in Raji B lymphocytes. EphA7, which had previously been described by 174 
our group to be critical for RRV infection of BJAB B lymphocytes, was used as control for Eph-175 
mediated infection. Expression of Plxdc1/2-Strep as well as EphA7-Strep dramatically enhanced 176 
susceptibility of Raji cells (Fig 4D, E). RRV-YFP wt infection increased from 0.14 ± 0.04% on empty 177 
vector transduced Raji cells to approx. 8.5% upon EphA7 overexpression and to approx. 17% upon 178 
Plxdc1/2 overexpression, without pronounced differences between the Plxdc family members. 179 
Mutation of the Eph-interaction motif in RRV-YFP gH-AELAAN completely abrogated the gain in 180 
susceptibility on EphA7 overexpressing cells while mutation of the Plxdc-interaction motif completely 181 
abrogated the gain in susceptibility on Plxdc1/2 overexpressing cells, confirming selective knockout 182 
of each individual receptor interaction in the respective mutant. Furthermore, deletion of the Eph-183 
interaction motif in RRV-YFP gH-AELAAN did not impact the infection of Plxdc1/2 overexpressing cells 184 
in comparison to RRV-YFP wt infection. In contrast, we observed an approx. 2-fold higher infection of 185 
RRV-YFP gH∆21-27 on EphA7 overexpression cells, when compared to RRV-YFP wt. Together, the 186 
blocking and overexpression experiments indicate an independent rather than cooperative nature of 187 
Eph and Plxdc receptor function. 188 
To quantitatively analyze the contribution of the Plxdc1/2-interaction to RRV infection of 189 
different cell types, RRV-YFP wt and RRV-YFP receptor binding mutant inocula were normalized to 190 
genome copies as determined by qPCR, and target cells were inoculated with the same number of 191 
encapsidated input virus genomes for wt and each mutant virus strain in an MOI range of 0.05 to 1 192 
on adherent cells. Infection as determined by the percentage of YFP+ cells was normalized to RRV wt, 193 
which was set to 1. For suspension cell lines, experiments with RRV wt infection over 1% were 194 
included in the analysis. Four (three for RF, five for MFB5487) independent sets of RRV wt and 195 
mutant stocks were used to compensate for variability in stock preparation. None of the analyzed 196 
adherent cell lines showed a preferential use of Plxdc receptors over Eph receptors based on the 197 
reduction of specific infectivity of Eph-binding and Plxdc-interaction-deficient mutants (Fig 5A). On 198 
rhesus monkey fibroblasts (RF), compared to RRV-YFP, RRV-YFP gH∆21-27, RRV-YFP gH-AELAAN and 199 
RRV-YFP gH∆21-27-AELAAN exhibited a decrease in infection of approx. 30%, 50% and 70%, 200 
respectively. Similarly on HaCaT, infection with RRV-YFP gH-AELAAN and RRV-YFP gH∆21-27-AELAAN 201 
was reduced by approx. 60% and 75%, respectively, compared to RRV-YFP. While RRV-YFP gH∆21-27 202 
exhibited a defect, comparable to RRV-YFP gH-AELAAN in three of the analyzed independent sets of 203 
RRV stocks, this reduction in infectivity did not reach significance due to one outlier. On SLK cells, 204 
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mutation of the Eph-interaction motif led to an approx. 65% decrease in infection, while RRV-YFP 205 
gH∆21-27 infection was on average comparable to RRV-YFP infection. In contrast, we identified B 206 
lymphocyte lines of human and macaque origin that exhibit a preference in the receptor usage for 207 
either Eph or Plxdc family members (Fig 5B). When normalized to genome copies, RRV-YFP gH∆21-27 208 
infection on human Raji lymphoblasts was comparable to RRV wt infection while mutation of the 209 
Eph-interaction motif lead to an approx. 90% decrease in infection, indicating preferential infection 210 
through Eph family receptors. Similarly, RRV-YFP gH∆21-27 exhibited only a minor defect (approx. 211 
20% reduced infection) on immortalized B lymphocytes of macaca mulatta origin (MMB1845) that 212 
did not reach significance, while infection with RRV-YFP gH-AELAAN and gH∆21-27-AELAAN was 213 
reduced by approx. 90% in comparison to RRV-YFP, again indicating preferential infection through 214 
Eph family receptors. Conversely, deletion of the Plxdc-interaction motif decreased infection of a B 215 
lymphocyte cell line of macaca fascicularis origin (MFB5487) by approx. 75% whereas RRV-YFP gH-216 
AELAAN exhibited an approx. 50% defect, indicating preferential use of the Plxdc interaction for 217 
infection of MFB5487 by RRV. Mutation of both the Eph- and Plxdc-interaction motif led to an even 218 
more pronounced defect of approx. 90%. 219 
To evaluate the contribution of potential attachment effects on the observed differences in 220 
specific infectivity, we analyzed the capacity of virions to bind Plxdc1/2 overexpressing Raji cells in 221 
comparison to empty vector transduced Raji cells (Fig 5C, D). The ratio of cell-bound viral DNA to 222 
input genomes was used as a surrogate marker for virus attachment. Mutation of the Plxdc- and Eph-223 
interaction motif had no detectable effect on attachment to control vector-transduced and Plxdc2-224 
overexpressing Raji cells. In contrast, Raji cells overexpressing Plxdc1 showed increased attachment 225 
of RRV-YFP 26-95 and RRV-YFP 26-95 gH-AELAAN, while attachment of Plxdc-interaction negative 226 
RRV-YFP 26-95 mutants gH∆21-27 and gH∆21-27-AELAAN was not enhanced and remained 227 
comparable to empty vector control and Plxdc2-overexpressing cells.  228 
To exclude effects of potential offsite genomic rearrangements in RRV-YFP 26-95 gH∆21-27 229 
we created two independent revertants (RRV 26-95 gH∆21-27rev9-4 and RRV 26-95 gH∆21-27rev10-3). 230 
Restoration of the residues deleted in RRV-YFP 26-95 gH∆21-27 restored infection on hPlxdc1/2-231 
transduced Raji, MFB5487 and HaCaT cells to RRV wt levels, with no pronounced differences 232 
between RRV wt, RRV 26-95 gH∆21-27rev9-4 and  RRV 26-95 gH∆21-27rev10-3 (Fig 5E). Similar to the 233 
approx. 11-fold increase of RRV wt infection upon hPlxdc1/2 overexpression, infection with RRV 234 
gH∆21-27 revertants increased from 2.00 ± 0.30% (2.54 ± 0.29%) on empty vector transduced Raji 235 
cells to 35.25 ± 1.21% (36.99 ± 0.39%) and 37.27 ± 0.68% (43.00 ± 0.99%) upon hPlxdc1 and hPlxdc2 236 




DISCUSSION  239 
In this study we identified the Plexin domain containing proteins 1 and 2 as a novel family of 240 
entry receptors for RRV. Plxdc1/2 interact with the gH/gL complex of RRV in a region close to the 241 
previously characterized binding motif for Eph receptors. While the Eph-interaction as well as the 242 
critical Eph binding motif in domain I of gH is conserved between RRV and the closely related human 243 
pathogenic KSHV (21), the interaction with Plxdc1/2 is exclusive to RRV and even exhibits differences 244 
between isolates 26-95 and 17577 as prototypic members of the described RRV sequence clades.  245 
According to our results, differences between Plxdc1 and Plxdc2 may also exist in terms of 246 
function. While overexpression of both Plxdc1 and Plxdc2 in Raji cells, that were virtually “non-247 
susceptible” under the conditions used, lead to robust RRV 26-95 infection (Fig 4D-E), only 248 
overexpression of Plxdc1 enhanced attachment of RRV wt and RRV gH-AELAAN in comparison to 249 
either non-transduced Raji cells or Plxdc-binding deficient RRV mutants (Fig 5D). Whether this is 250 
primarily due to differences in expression levels, consistently observed between Plxdc1 and Plxdc2 251 
upon lentiviral overexpression or due to underlying functional differences in the gH interaction with 252 
these molecules remains to be determined. 253 
Mutation of residues Tyr23 and Glu25 in gH domain I which are conserved between RRV 254 
isolate 26-95 and 17577 almost abolished the interaction with Plxdc2, which is bound by gH/gL of 255 
both isolates. Although the same residues are critical for the interaction of RRV gH 26-95 with Plxdc1, 256 
the partial conservation of the region appears to be insufficient to confer binding of 17577 gH to 257 
Plxdc1. Interestingly, the interaction of 17577 gH with Plxdc2 is dependent on the presence of gL in 258 
the gH/gL complex, whereas 26-95 gH is able to bind Plxdc1/2 independent of gL. These features of 259 
Plxdc1/2 binding specificities appear similar to the interaction of the gH/gL complex with Eph 260 
receptors, wherein mutation of the strictly conserved Eph interaction motif is sufficient to abrogate 261 
receptor binding, but differences in KSHV and RRV affinities for A- and B-type Eph RTKs indicate the 262 
existence of additional regions in gH or gL that contribute to or modulate the interaction. Whether 263 
these preferences for different members of conserved receptor families also influence e.g. cell or 264 
tissue tropism, viral spread or pathogenicity has not been determined. Sequence comparisons of 265 
over twenty RRV isolates identified dramatic differences in the extracellular domains of gH as well as 266 
in gL between isolates that fell in two discrete groupings either similar to 26-95 or 17577, while 267 
variation in other glycoproteins R1, gM, gN, orf68 was minimal between clades (4). However, if these 268 
clade-specific glycoprotein variations influence the observed differences in pathogenicity between 269 
RRV strains 26-95 and 17577 remains to be seen. Another interesting question would be if the 270 
receptor-binding function of the N-terminal region of gH is conserved between RRV and KSHV, and 271 
probably EBV, and whether KSHV and EBV can bind another receptor through this region. So far, we 272 
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did not to identify corresponding interactions for KSHV, but in principle the region of gH is present in 273 
both viruses and it is tempting to assume some functional conservation. 274 
Along those lines, the evolutionary factors that drive interaction with different receptor 275 
families and the resulting multitude of herpesvirus–receptor interactions is highly interesting. For e.g. 276 
EBV and HCMV, a clear correlation between receptor usage, dependent on viral interaction partners 277 
of the gH/gL complex, and cell tropism has been demonstrated in various studies ((34), reviewed in 278 
(35)). However, for rhadinoviruses, the picture is less clear. Even though we could show that RRV 279 
infection of select cell lines exhibited a dependence on specific receptors, e.g. Raji infection was 280 
dependent on the gH/gL – Eph interaction, MFB5487 infection was more dependent on the Plxdc-281 
interaction (Fig 5) and similarly mutation of the Eph-interaction motif did not impact infection on all 282 
cell types equivalently (21), a definite correlation between exclusive receptor usage and infection of 283 
specific cell types is still missing. While the notion of a role of different receptor interactions in KSHV 284 
and RRV cell and tissue tropism is tempting, the possibility of a redundant function should not be 285 
discarded. Redundancy could be driven by the need to escape antibodies e.g. to one receptor binding 286 
site. For instance, in vitro infection of human keratinocytes or rhesus fibroblasts seemed to be 287 
impacted to a similar degree by either deletion of the Eph- or of the Plxdc-interaction motif (Fig 5). 288 
To ultimately address the correlation between receptor- and tissue-tropism, in vivo studies using 289 
receptor-de-targeted mutants to analyze cell and tissue tropisms will be required. The importance of 290 
in vivo studies is also supported by a recent report that showed that a gL-null RRV mutant still 291 
established persistent infection in the B cell compartment upon intravenous inoculation, while 292 
infection of B cells in vitro was drastically reduced (22), a finding that could be explained by the gL-293 
independent usage of Plxdc1/2 for B cell infection in vivo.  294 
On a more speculative note, the apparent overlap between virus receptors and tumor-295 
associated membrane proteins may represent an interesting research subject. Eph receptors were 296 
first identified in an attempt to characterize tyrosine kinases involved in cancer (36) and altered 297 
expression in various cancer types has been demonstrated for several Eph family members (reviewed 298 
in (37)). Similarly, Plxdc1 was first described in a screen for novel tumor endothelial members (23) 299 
and expression of both Plxdc1 and Plxdc2 is elevated in the endothelium of solid tumors (23, 24, 38, 300 
39). Plxdc1 expression has been described as prognostic marker and modulating factor for various 301 
human cancers (38–42). Given the similarity in changes of e.g. metabolic, transcriptional, and 302 
signaling networks in cancer cells and upon virus infection it is not unlikely that either elevated 303 
expression or signaling of these molecules is favorable for both virus infection and cancer 304 








Figure 1 Plxdc family receptors are novel interaction partners for the RRV gH/gL. A) 311 
Immunoprecipitation of recombinant soluble RRV 26-95 gH-FcStrep in the presence or absence of 312 
293T lysate. Precipitates were analyzed by PAGE, silver stained and bands at the indicated molecular 313 
weight (arrows, regions a-d) were excised and analyzed by mass spectrometry. Numbers in brackets 314 
indicate the number of Plxdc2 peptides identified by LC-MS/MS in each region. B) V5-tagged RRV 315 
26-95 gH, RRV 17577 gH or KSHV gH alone or co-expressed with the respective Flag-tagged gL 316 
construct were immunoprecipitated in the presence of full-length Plxdc1 or Plxdc2 from human (h) or 317 
macaca mulatta (mm) origin using monoclonal antibody to the V5-tag.  Precipitates were analyzed by 318 
Western blot with the indicated antibodies. C) Co-immunoprecipitation of soluble human Plxdc1-319 
FcStrep or human Plxdc2-FcStrep with RRV 26-95 gH-V5/gL-Flag or RRV 17577 gH-V5/gL-Flag using 320 
StrepTactin Sepharose in the presence or absence of human full-length EphB3. Abbreviations: IP: 321 




Figure 2 Plxdc1/2 function as entry receptors for RRV. A) List of BAC-derived recombinant viruses 324 
and introduced mutations used in this figure. B) Dose-dependent inhibition of RRV 26-95 infection by 325 
soluble human Plxdc2-FcStrep on HaCaT cells. RRV-YFP 26-95 wt and RRV-YFP 26-95 gH-AELAAN were 326 
pre-incubated with hPlxdc2-FcStrep for 30min at room temperature. FcStrep alone was used as 327 
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control. YFP expression as indicator of infection was measured by flow cytometry. Infection in the 328 
presence of 0.4nM FcStrep was set to 100% (MOI ~0.2, triplicates, error bars represent SD). C) 329 
Inhibition of RRV 26-95 infection by soluble Plxdc2-Fc and EphB3-Fc on HaCaT cells. RRV-YFP 26-95 wt 330 
and RRV-YFP 26-95 gH-AELAAN were pre-incubated with 100nM hPlxdc2-FcStrep, 10nM EphB3-Fc or 331 
a combination of 100nM hPlxdc2-FcStrep and 10nM EphB3-Fc for 30min at room temperature. 332 
FcStrep alone was used as control. YFP expression as indicator of infection was measured by flow 333 
cytometry. Infection with FcStrep was set to 100% (MOI ~0.2, triplicates, error bars represent SD). D) 334 
Inhibition of RRV 26-95 infection by soluble human Plxdc2-FcStrep on SLK cells and rhesus fibroblasts. 335 
RRV-YFP 26-95 wt and RRV-YFP 26-95 gH-AELAAN were pre-incubated with 250nM hPlxdc2-FcStrep 336 
for 30min at room temperature. FcStrep alone was used as control. YFP expression as indicator of 337 
infection was measured by flow cytometry. Infection with FcStrep was set to 100% (MOI ~0.05-0.1, 338 
triplicates, error bars represent SD). E) Raji cells were transduced with TwinStrep-tagged human 339 
Plxdc1 and Plxdc2 (hPlxdc1-Strep/ hPlxdc2-Strep) expression constructs or an empty vector control, 340 
briefly selected and infected with RRV-YFP 26-95 wt or RRV-YFP 26-95 gH-AELAAN normalized to 341 
genome copies as determined by qPCR. Micrographs show representative infection of the indicated 342 
cell pools. F) Lysates of transduced Raji cell pools were analyzed for Plxdc1/2-Strep expression by 343 
Western blot. G) Quantification of (E) by flow cytometric analyses of YFP reporter gene expression as 344 









Figure 3 An amino acid sequence motif in the N-terminal region of RRV 26-95 and RRV 17577 gH is 352 
essential for the Plxdc-interaction. A) Multiple sequence alignment of the N-terminal region of gH of 353 
KSHV and the two RRV isolates 26-95 and 17577. Boxes indicate the binding motives for Eph 354 
receptors (green) and Plxdc receptors (blue). B) Homology-based structure prediction of the RRV 26-355 
95 gH/gL complex based on the crystal structure of the EBV gH/gL complex (PDB number 3PHF) using 356 
the Iterative Threading ASSembly Refinement (I-TASSER) server and the CO-THreader (COTH) 357 
algorithms for protein-protein complex structure and multi-chain protein threading. The Eph 358 
receptor interaction motif is shown in green, the Plxdc interaction motif is shown in blue, gL is shown 359 
in red, gH is shown in grey. C) Deletion of the Plxdc-interaction motif in RRV 26-95 gH (amino acid 21-360 
27, “YEYNEEK”) abrogates gH interaction with Plxdc1 and Plxdc2.  V5-tagged gH wt or gH∆21-27 were 361 
immunoprecipitated in the presence of full-length human or macaca mulatta Plxdc1-myc or Plxdc2-362 
myc using monoclonal antibody to the V5-tag. Precipitates were analyzed by Western blot. D) 363 
Deletion of the Plxdc-interaction motif in RRV 17577 gH (amino acid 21-26, “YVYDEK”) abrogates gH 364 
interaction with Plxdc2.  V5-tagged gH wt or gH∆21-26 was co-expressed with Flag-tagged RRV 17577 365 
gL. gH-V5/gL-Flag complexes were immunoprecipitated in the presence of full-length human or 366 
macaca mulatta Plxdc1-myc or Plxdc2-myc using monoclonal antibody to the V5-tag. Precipitates 367 
were analyzed by Western blot. E) Mutational scan of Plxdc-interaction motif (amino acid 21-27, 368 
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“YEYNEEK”) of RRV 26-95 gH identifies human Plxdc1/2-interacting residues. V5-tagged gH mutants 369 
were immunoprecipitated in the presence of full-length human Plxdc1-myc or Plxdc2-myc using 370 
monoclonal antibody to the V5-tag. Precipitates were analyzed by Western blot. RRV gH∆21-27 371 
serves as negative control. F) Mutational scan of Plxdc-interaction motif (amino acid 21-27, 372 
“YEYNEEK”) of RRV 26-95 gH identifies rhesus macaque Plxdc1/2-interacting residues. V5-tagged gH 373 
mutants were immunoprecipitated in the presence of full-length human Plxdc1-myc or Plxdc2-myc 374 
using monoclonal antibody to the V5-tag. Precipitates were analyzed by Western blot. RRV gH∆21-27 375 
serves as negative control. Abbreviations: IP: immunoprecipitation, IB: immunoblotting, h: human, 376 







Figure 4 Deletion of the seven amino acid Plxdc-binding motif is sufficient to detarget RRV 26-95 382 
from Plxdc receptors A) List of BAC-derived recombinant viruses and introduced mutations used in 383 
this figure. B) Dose-dependent inhibition of RRV-YFP 26-95 infection by soluble human Plxdc2-384 
FcStrep on HaCaT cells. RRV-YFP 26-95 wt, RRV-YFP 26-95 gH-AELAAN, RRV-YFP 26-95 gH∆21-27 and 385 
RRV-YFP 26-95 gH∆21-27-AELAAN were pre-incubated with hPlxdc2-FcStrep for 30min at room 386 
temperature. FcStrep alone was used as control. YFP expression as indicator of infection was 387 
measured by flow cytometry. Infection in the presence of 0.4nM FcStrep was set to 100% (MOI 388 
~0.05, triplicates, error bars represent SD). C) Inhibition of RRV 26-95 infection by soluble Plxdc2-Fc 389 
and EphB3-Fc on HaCaT cells. RRV-YFP 26-95 wt, RRV-YFP 26-95 gH-AELAAN, RRV-YFP 26-95 gH∆21-390 
27 and RRV-YFP 26-95 gH∆21-27-AELAAN were pre-incubated with 100nM hPlxdc2-FcStrep, 10nM 391 
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EphB3-Fc or a combination of 100nM hPlxdc2-FcStrep and 10nM EphB3-Fc for 30min at room 392 
temperature. FcStrep alone was used as control. YFP expression as indicator of infection was 393 
measured by flow cytometry. Infection with FcStrep was set to 100% (MOI ~0.1-0.2, triplicates, error 394 
bars represent SD). D) Raji cells were transduced with TwinStrep-tagged human EphA7, Plxdc1 or 395 
Plxdc2 (hEphA7-Strep, hPlxdc1-Strep, hPlxdc2-Strep) expression constructs or an empty vector 396 
control, briefly selected and infected with RRV-YFP 26-95 wt, RRV-YFP 26-95 gH-AELAAN, RRV-YFP 397 
26-95 gH∆21-27 or RRV-YFP 26-95 gH∆21-27-AELAAN normalized to genome copies as determined by 398 
qPCR. YFP expression as indicator of infection was measured by flow cytometry. The mean across 399 
three independent sets of RRV stocks is indicated by columns. The means of individual triplicate 400 
infections for each set of RRV stocks are given as symbols within the respective columns. E) 401 




Figure 5 The contribution of the RRV 26-95 gH-Plxdc interaction to infection is cell type-specific and 404 
may in part be dependent on attachment effects. A) RRV 26-95 deleted in the Plxdc-interaction 405 
motif exhibits reduced specific infectivity on HaCaT and RF, but not SLK cells. Target cells were 406 
infected with RRV-YFP 26-95 wt, RRV-YFP 26-95 gH-AELAAN, RRV-YFP 26-95 gH∆21-27 or RRV-YFP 407 
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26-95 gH∆21-27-AELAAN normalized to genome copies as determined by qPCR. YFP expression as 408 
indicator of infection was measured by flow cytometry and normalized to RRV-YFP 26-95 wt 409 
infection. Means of individual normalized infections with three (RF) or four (HaCaT, SLK) independent 410 
sets of RRV stocks are given as symbols of different color. Sets with RRV-YFP 26-95 wt infection in an 411 
MOI range of 0.05 - 1 were used for analysis. The mean across the independent sets of RRV stocks is 412 
indicated by black lines. B) RRV 26-95 deleted in the Plxdc-interaction motif exhibits reduced specific 413 
infectivity on MFB5487, but not Raji and MMB1845 cells. Target cells were infected with RRV-YFP 26-414 
95 wt, RRV-YFP 26-95 gH-AELAAN, RRV-YFP 26-95 gH∆21-27 or RRV-YFP 26-95 gH∆21-27-AELAAN 415 
normalized to genome copies as determined by qPCR. YFP expression as indicator of infection was 416 
measured by flow cytometry and normalized to RRV-YFP 26-95 wt infection. Means of individual 417 
normalized infections with four (Raji, MMB1845) or five (MFB5487) independent sets of RRV stocks 418 
are given as symbols of different color. Sets with RRV-YFP 26-95 wt infection exceeding 1% were used 419 
for analysis. The mean across the independent sets of RRV stocks is indicated by black lines. C) 420 
Western blot analysis of Raji cells transduced with TwinStrep-tagged human Plxdc1 and Plxdc2 421 
(hPlxdc1-Strep/ hPlxdc2-Strep) expression constructs or an empty vector control. D) Attachment of 422 
RRV 26-95 on transduced Raji cells is affected by hPlxdc1-Strep, but not hPlxdc2-Strep 423 
overexpression. Cells, analyzed in (C), were incubated with cold virus at the indicated concentrations 424 
at 4°C for 30min followed by genomic DNA isolation. The ratio of viral to cellular DNA as 425 
measurement for attached virus was calculated based on ΔCt values of a genomic (CCR5) and a viral 426 
locus (ORF73/ LANA) as determined by qPCR and plotted against input viral genome number. E) Re-427 
introduction of the seven amino acid motif crucial for Plxdc-interaction rescues RRV-YFP 26-95 428 
gH∆21-27 infection. Transduced Raji cells, analyzed in (C), were infected with RRV-YFP 26-95 wt, RRV-429 
YFP 26-95 gH-AELAAN, RRV-YFP 26-95 gH∆21-27, RRV-YFP 26-95 gH∆21-27-AELAAN or two RRV-YFP 430 
26-95 gH∆21-27 revertants (RRV-YFP 26-95 gH∆21-27rev9-4, RRV-YFP 26-95 gH∆21-27rev10-3) normalized 431 
to genome copies as determined by qPCR. YFP expression as indicator of infection was measured by 432 
flow cytometry (triplicates, error bars represent SD).  433 
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MATERIAL AND METHODS 434 
Cells. Human embryonic kidney (HEK) 293T cells (RRID:CVCL_0063) (laboratory of Tobias Moser), SLK cells 435 
(RRID:CVCL_9569) (NIH AIDS Research and Reference Reagent program), rhesus monkey fibroblasts (RF) 436 
(laboratory of Prof. Rüdiger Behr) and HaCaT human keratinocytes (RRID:CVCL_0038) were cultured in 437 
Dulbecco’s Modified Eagle Medium (DMEM), high glucose, GlutaMAX, 25mM HEPES (Thermo Fisher Scientific) 438 
supplemented with 10% fetal calf serum (FCS) (Thermo Fisher Scientific), and 50μg/ml gentamycin (PAN 439 
Biotech). iSLK cells (laboratory of Don Ganem, Novartis Institutes for BioMedical Research, Emeryville, CA, USA) 440 
were maintained in DMEM supplemented with 10% FCS, 50μg/ml gentamycin, 2.5μg/ml puromycin (InvivoGen) 441 
and 250μg/ml G418 (Carl Roth). Raji cells (RRID:CVCL_0511) (laboratory of Jens Gruber), MFB5487 (a clonal cell 442 
line established from macaca fascicularis PBMC, immortalized by infection with herpesvirus papio; a kind gift 443 
from Ulrike Sauermann) and MMB1845 cells (a clonal cell line established from macaca mulatta PBMC, 444 
immortalized by infection with herpesvirus papio; a kind gift from Ulrike Sauermann) were cultured in RPMI 445 
(Thermo Fisher Scientific) supplemented with 10% FCS and 50μg/ml gentamycin. 446 
BAC mutagenesis and virus production. RRV recombinants (RRV gHΔ21-27, RRV gHΔ21-27-AELAAN) were 447 
generated based on BAC35-8 (43) and RRV gH-AELAAN (21) respectively, using a two-step, markerless λ-red-448 
mediated BAC recombination strategy as described by Tischer et al. (33). In short, recombination cassettes 449 
were generated from the pEPKanS template by polymerase chain reaction (PCR) with Phusion High Fidelity DNA 450 
polymerase (Thermo Fisher Scientific) using long oligonucleotides (Ultramers; purchased from Integrated DNA 451 
Technologies (IDT)) (see S1 Table for a complete list of primers). Recombination cassettes were transformed 452 
into RRV-YFP-carrying GS1783 followed by kanamycin selection, and subsequent second recombination under 453 
1% L(+)arabinose (Sigma-Aldrich)-induced I-SceI expression. Colonies were verified by PCR of the mutated 454 
region followed by sequence analysis (Macrogen), pulsed-field gel electrophoresis and restriction fragment 455 
length polymorphism. For this purpose, bacmid DNA was isolated by standard alkaline lysis from 5ml liquid 456 
cultures. Subsequently, the integrity of bacmid DNA was analyzed by digestion with restriction enzyme XhoI 457 
and separation in 1% PFGE agarose (Bio-Rad) gels and 0.5×TBE buffer by pulsed-field gel electrophoresis at 6 458 
V/cm, 120-degree field angle, switch time linearly ramped from 1s to 5s over 16 h (CHEF DR III, Bio-Rad). 459 
Infectious RRV-YFP recombinants were generated as described previously (21). In short, bacmid DNA 460 
(NucleoBond Xtra Midi) was transfected into 293T cells using GenJet Ver. II (Signagen) according to 461 
manufacturer’s instructions. Transfected 293T cells were transferred onto a confluent rhesus monkey 462 
fibroblasts monolayer two days after transfection and co-cultivated until a visible cytopathic effect (CPE) was 463 
observed. For virus stocks preparations, confluent primary rhesus monkey fibroblasts were inoculated with 464 
infectious supernatant of 293T/rhesus monkey fibroblast co-cultures. After multiple rounds of replication virus-465 
containing RF supernatant was clarified by centrifugation (4750g, 10 minutes), concentrated by overnight 466 
centrifugation (4200rpm, 4°C) and careful aspiration of approximately 95% of the supernatant. The pellet was 467 
resuspended overnight in the remaining liquid. Stocks of wt and recombinant viruses were aliquoted and 468 
stored at -80°C. Mutations were verified by PCR amplification of the respective region followed by sequence 469 
analysis (Macrogen). 470 
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Plasmids. The pcDNA4 vector containing full-length EphB3 (ref|BC052968|, pcDNA-EphB3-myc), pcDNA6aV5 471 
vectors containing RRV/KSHV gH and gL coding sequences (ref|GQ994935.1|, pcDNA6aV5-KSHV-gH, pcDNA3.1-472 
KSHV-gL-Flag (13); ref|AF210726.1|, pcDNA6aV5-RRV-26-95-gH, pcDNA3.1-RRV-26-95-gL-Flag (14, 44); 473 
ref|AF083501.3|, pcDNA6aV5-RRV-17577-gH, pcDNA3.1-RRV-17577-gL-Flag (14)) were described elsewhere.  474 
RRV 26-95/ RRV 17577 recombinant gH constructs were generated based on pcDNA6aV5-RRV-26-95-gH or 475 
pcDNA6aV5-RRV-17577-gH, respectively, using ‘Round the Horn Site-directed mutagenesis. Expression 476 
plasmids pcDNA4-hPlxdc1-myc (Homo sapiens, full-length, ref |NM_020405.5|) and pcDNA4-hPlxdc2-myc 477 
(Homo sapiens, full-length, ref |NM_032812.9|) were generated by PCR based restriction cloning. The soluble 478 
ectodomain of human Plxdc2 (amino acids 31-453) without signal peptide was inserted behind a heterologous 479 
signal peptide of murine IgG-kappa into pAB61Strep by PCR based restriction cloning, resulting in a C-terminally 480 
fused IgG1 Fc-fusion protein with a C-terminal tandem Strep-Tag (pPlxdc2-FcStrep) as described previously 481 
(45). Expression plasmids pcDNA4-mmPlxdc1-myc (macaca mulatta, full-length, ref |XM_028836436.1|) and 482 
pcDNAmmPlxdc2-myc (macaca mulatta, full-length, ref |XM_028826043.1|) were generated based on PCR-483 
amplified gBlock gene fragments (purchased from IDT) of the regions varying from human Plxdc1 (nt1-1200) 484 
and Plxdc2 (nt1-1401), respectively, and ligated in the respective PCR-amplified backbone (pcDNA4hPlxdc1-485 
myc, pcDNA4hPlxdc2-myc) by exonuclease-based Gibson-assembly (Gibson Assembly Mastermix, New England 486 
Biolabs). pLenti CMV Blast DEST (706-1) (a gift from Eric Campeau & Paul Kaufman (Addgene plasmid #17451)) 487 
constructs carrying a  human Plxdc1-TwinStrep or Plxdc2-TwinStrep expression cassette (pLenti-CMV-Blast-488 
Plxdc1-Strep/ pLenti-CMV-Blast-Plxdc2-Strep) were based on pcDNA4-hPlxdc1-myc/ pcDNA4-hPlxdc2-myc, 489 
which were PCR-amplified and ligated using exonuclease-based Gibson-assembly. pLenti-CMV-Blast-EphA7-490 
Strep was described before (19). (See S1 Table for a complete list of primers and constructs). 491 
 492 
Recombinant proteins. Recombinant, soluble FcStrep and Plxdc2-FcStrep-fusion proteins were purified under 493 
native conditions by Strep-Tactin chromatography from 293T cell culture supernatant. 293T cells were 494 
transfected using Polyethylenimine "Max" (PEI) (Polysciences) (46)  as described before (19) with pAB61Strep 495 
or pPlxdc2-FcS. The protein-containing cell culture supernatant was filtered through 0.22μm PES membranes 496 
(Millipore) and passed over 0.5ml of a Strep-Tactin Superflow (IBA Lifesciences) matrix in a gravity flow 497 
Omniprep column (BioRad). Bound protein was washed with approximately 50ml phosphate buffered saline pH 498 
7.4 (PBS) and eluted in 1ml fractions with 3mM desthiobiotin (Sigma-Aldrich) in PBS. Protein-containing 499 
fractions were pooled and buffer exchange to PBS via VivaSpin columns (Sartorius) was performed. Protein 500 
concentration was determined by absorbance at 280nm. Aliquots were frozen and stored at −80°C. 501 
Recombinant, human, soluble EphB3-Fc (5667-B3-050) was purchased from R&D Systems.  502 
Lentivirus production and transduction. For production of lentiviral particles, 10cm cell culture grade petri 503 
dishes of approximately 80% confluent 293T cells were transfected with 1.4μg pMD2.G (VSV-G envelope 504 
expressing plasmid, a gift from Didier Trono (Addgene plasmid #12259), 3.6µg psPAX2 (Gag-Pol expression 505 
construct, a gift from Didier Trono (Addgene plasmid #12260), and 5μg of lentiviral expression constructs 506 
(pLenti CMV Blast DEST (706-1), pLenti-CMV-Blast-EphA7-Strep, pLenti-CMV-Blast-Plxdc1-Strep, pLenti-CMV-507 
Blast-Plxdc2-Strep) using PEI as described before (19). The supernatant containing the pseudotyped lentiviral 508 
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particles was harvested 2 to 3 days after transfection and filtered through 0.45μm CA membranes (Millipore). 509 
For transduction, lentivirus stocks were used at a 1:5 dilution unless stated otherwise. After 48h, the selection 510 
antibiotic blasticidin (Invivogen) was added to a final concentration of 10µg/ml. After initial selection the 511 
blasticidin concentration was reduced to 5µg/ml. 512 
Quantitative realtime-PCR-based viral genome copy number analysis and virus attachment assay. 513 
Concentrated virus samples were treated with DNAseI (0.1 units/μl) to remove any non-encapsidated DNA 514 
(37°C, overnight). Subsequently, DNAseI was deactivated and viral capsids were disrupted by heating the 515 
samples to 95°C for 30 minutes. Realtime-PCR (qPCR) was performed on a StepOne Plus cycler (Thermo Fisher 516 
Scientific) in 20μl reactions using the SensiFAST Probe Hi-ROX Kit (Bioline) (cycling conditions: 3min initial 517 
denaturation at 95°C, 40 cycles 95°C for 10s and 60°C for 35s). All primer-probe sets were purchased from IDT 518 
as complete PrimeTime qPCR Assays (primer:probe ratio = 4:1). Samples were analyzed in technical triplicates. 519 
A series of five 10-fold dilutions of bacmid DNA was used as standard for absolute quantification of viral 520 
genome copies based on qPCR of ORF73 for RRV (see S1 Table for a complete list of primers). For virus 521 
attachment assays transduced Raji cells were incubated with ice-cold virus dilutions at the indicated 522 
concentrations, normalized to genomes per cell, at 4°C for 30min. After three washes with ice-cold PBS 523 
genomic DNA was isolated using the ISOLATE II Genomic DNA Kit (Bioline) according to manufacturer’s 524 
instructions. Genome copies of used input virus preparations were determined after overnight DNAseI digest 525 
as described above. Relative values of bound viral genomes to cellular DNA were calculated on the basis of ΔCt 526 
values for viral genomic loci (ORF73 for RRV) and a cellular genomic locus (CCR5) using the same conditions 527 
described above. For attachment assays all samples were analyzed in technical duplicates.  528 
Infection assays, blocking experiments and flow cytometry. For infection assays cells were plated at 50 000 529 
cells/cm2 (SLK, HaCaT, Raji), 25 000 cells/cm2 (RF) or 200 000 cells/ml (Raji, MFB5487, MMB1845) respectively. 530 
One day after plating (for adherent cells lines) or directly after plating (for suspension cell lines), cells were 531 
infected with the indicated amounts of virus. Adherent cells lines were harvested 24h post infection by brief 532 
trypsinization, followed by addition of 5% FCS in PBS to inhibit trypsin activity. Suspension cell lines were 533 
harvested 48h post infection (24h post infection for transduced Raji cells) by pipetting. Subsequently, cells 534 
were pelleted by centrifugation (1200rpm, 10min), washed once with PBS, re-pelleted and fixed in PBS 535 
supplemented with 4% formaldehyde (Carl Roth). Block of RRV infection with soluble decoy receptor was 536 
assayed by infection with virus inocula that were pre-incubated with the indicated concentrations of soluble 537 
EphB3-Fc, hPlxdc1-Fc, hPlxdc2-Fc or Fc alone at room temperature for 30min. Calculation of molarity was based 538 
on diametric proteins. Cell harvest and preparation for flow cytometry analyses was performed as described 539 
above. A minimum of 5 000 – 10 000 cells was analyzed per sample for YFP expression on a LSRII flow 540 
cytometer (BD Biosciences). Data was analyzed using Flowing Software (Version 2.5).  541 
Immunoprecipitation and Western blot analysis. For interaction analysis of gH-V5/gL-Flag complexes with 542 
Plxdc1/2, 293T cells were transfected using PEI as described before. Lysates of 293T cells transfected with the 543 
respective expression constructs for recombination gH-V5/gL-Flag complexes were prepared in NP40 lysis 544 
buffer (1% Nonidet P40 Substitute (Sigma-Aldrich), 150mM NaCl (Sigma-Aldrich), 50mM HEPES (VWR), 1mM 545 
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EDTA (Amresco) with freshly added Protease Inhibitor Cocktail, General Use (Amresco)) and protein content 546 
was determined by Bradford assay using Roti-Quant (Roth) according to manufacturer’s instructions. 20µg total 547 
protein was denatured in 1x SDS sample buffer (Morris formulation) at 95°C for 5min, separated by 548 
polyacrylamide gel electrophoresis (PAGE) using 8–16% Tris-Glycine polyacrylamide gradient gels (Thermo 549 
Fisher Scientific) with Tris-Glycine SDS running buffer (25mM Tris, 192mM glycine, 0.1% SDS) and transferred to 550 
0.45µm (0.22µm for blots containing gL) Polyvinylidendifluorid (PVDF) membranes (200mA/Gel, max 30V, 1h in 551 
Towbin buffer (25mM Tris, 192mM glycine) with 20% methanol) in a wet tank system (Mini Blot Module, 552 
Thermo Fisher). The membranes were blocked in 5% dry milk powder in TBS-T (5mM Tris, 15mM NaCl, 0.05% 553 
Tween20) for 1h, at room temperature, washed once in TBS-T and  incubated with the respective antibodies for 554 
2h at room temperature or overnight at 4°C (see S1 Table for a complete list of antibodies). After three washes 555 
with TBS-T, the membranes were incubated with the respective HRP-conjugated secondary antibody in 5% dry 556 
milk powder in TBS-T for 1h at room temperature washed three times in TBS-T and imaged on an ECL 557 
ChemoCam 3.2 Imager (Intas) using Immobilon Forte Western HRP substrate (Merck Millipore). For pulldown of 558 
gH-V5 or gH-V5/ gL-Flag complexes, the amount of input lysate between wt and mutant gH constructs was 559 
normalized to gH expression as determined by Western blot and diluted to equal volume with cell lysate from 560 
non-transfected 293T cells prior to immunoprecipitation. Subsequently, lysates were incubated with 0.5µg V5-561 
tag antibody (Bio-Rad) and ProteinG sepharose (GenScript) overnight at 4°C with agitation. After three washes 562 
in NP40 lysis buffer, ProteinG beads with pre-coupled complexes were incubated overnight at 4°C with 563 
agitation with lysate of full-length human or macaca mulatta Plxdc1-myc or Plxdc2-myc expression plasmid 564 
transfected 293T cells normalized to Plxdc expression. Volumes were adjusted with lysate from untransfected 565 
293T cells. ProteinG beads were collected by brief centrifugation and washed 3 times in NP40 lysis buffer. 566 
Precipitates were heated in 2x SDS sample buffer (95°C, 5min) and analyzed by Western blot as described 567 
above. For co-immunoprecipitation of soluble Plxdc1/2-Strep constructs with gH-V5/gL-Flag and EphB3-myc, 568 
supernatant of Plxdc1/2-FcStrep transfected 293T cells was incubated with StrepTactinXT beads (IBA) overnight 569 
at 4°C with agitation. After three washes in NP40 lysis buffer, StrepTactinXT beads with pre-coupled Plxdc1/2-570 
Strep were incubated overnight at 4°C with agitation with equal amounts of lysate of full-length human EphB3-571 
myc, RRV 26-95 gH-V5/gL-Flag or 17577 gH-V5/gL-Flag expression plasmid transfected 293T cells or the 572 
indicated combinations. Volumes were adjusted with lysate of untransfected 293T cells. 573 
Structure prediction and analysis. Homology based structure prediction was performed using the Iterative 574 
Threading ASSembly Refinement (I-TASSER) server on standard settings for structure prediction of RRV 26-95 575 
gH and gL based on the crystal structure of the EBV gH/gL complex (3PHF). Modeling of the RRV 26-95 gH/gL 576 
complex was additionally performed using both the SPRING and CO-THreader algorithms for protein-protein 577 
complex structure and multi-chain protein threading with no differences between determined structures. 578 
Resulting I-TASSER structures were aligned to the gH/gL CO-THreader model with the VMD 1.9.3 OpenGL RMSD 579 
Trajectory Tool based on amino acids 25 to 62 of gH (RMSD of 0.344Å) and amino acids 2 to 100 of gL (RMSD of 580 
2.697Å) to generate the depicted model. All further analyses and visualizations were performed using VMD 581 
1.9.3 OpenGL.  582 
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Mathematical and statistical analysis. Statistical difference between groups was determined by unpaired 583 
Student’s t-tests followed by Bonferroni correction for multiple comparisons. All Statistical analyses were 584 
performed with GraphPad Prism version 6. For all statistics, *: p-value < 0.05, **: p-value < 0.01, ***: p-value < 585 
0.001, ns: not significant. 586 
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S1 Table  List of primers, and antibodies used in this study.
A) Oligos for BAC recombination, sequencing and qPCR
name sequence
BAC mutagenesis RRV 26-95 gH∆21-27 forward 5'-CACTGTTTGTGTTTGTTGGTAATTACATTGTCTGTAATTAATGGAGTACCGGGACTTGAAATAGTAGGATGACGACGATAAGTAGGG-3'
RRV 26-95 gH∆21-27 reverse 5'-TGTTGTTGTGGCAGGGGTAAGAAGAACTATTTCAAGTCCCGGTACTCCATTAATTACAGACAATGCAACCAATTAACCAATTCTGATTAG-3'
RRV 26-95 gH∆21-27rev forward 5'-CACTGTTTGTGTTTGTTGGTAATTACATTGTCTGTAATTAATGGATATGAATATAATGAAGAAAAGGTACCGGGACTTGAAATAGTAGGATGACGACGATAAGTAGGG-3'
RRV 26-95 gH∆21-27rev reverse 5'-TGTTGTTGTGGCAGGGGTAAGAAGAACTATTTCAAGTCCCGGTACCTTTTCTTCATTATATTCATATCCATTAATTACAGACAATGCAACCAATTAACCAATTCTGATTAG-3'
Sequencing PCR RRV 26-95 gHΔ21-27seq forward 5'-TCCAGATTGACTCATCGGTTTC-3'
RRV 26-95 gHΔ21-27seq reverse 5'-TCCAATCGGCTGTCATAATACC-3'
qPCR RRV 26-95 ORF73 primer1
primer2
probe
genomic CCR5 primer1 5'-CCCAGTGGGACTTTGGAAATA-3'
(human/ rhesus) primer2 5'-CGATTGTCAGGAGGATGATGAA-3'
probe 5'-/56-FAM/TGTGTCAAC/ZEN/TCTTGACAGGGCTCT/3IABkFQ/-3'
B) Primers for restricton mediated, Gibson Assembly and Around-the-horn cloning
vector/ based on Primer vector Primer insert
PCR based pcDNA4MH-hPlxdc1 pcDNA4-MH XbaI x KpnI digest 5'-AA GGTACC ATGCGAGGCGAGCTCTGGC-3'
restriction cloning 5'-AA TCTAGA GCACTGCTCAGCCTCCATGAAG -3'
pcDNA4MH-hPlxdc2 pcDNA4-MH XbaI x KpnI digest 5'-AA GGTACC ATGGCGAGGTTCCCGAAGGC-3'
5'-AA TCTAGA GCACTGCTCTGATACAATAAAGC-3'
Gibson Assembly pcDNA-hPlxdc1-Strep pAB61strep GCGCGCCGTACGAAGCTTGGTACCCTGAGCCCCCAGCCCGGAGCAGG 5'-GGCGGCCGCTGTGACAAAACTCAC-3'
GTGAGTTTTGTCACAGCGGCCGCCCAGGTGCACAGGAGTGCCCTTTGTC 5'-GGTACCAAGCTTCGTACGGCGCGC-3'
pcDNA-hPlxdc2-Strep pAB61strep KpnI x NotI digest 5'-AAGGTACC AAACCCGGAGACCAAATCCTTG-3'
5'-TGCGGCCGCC GTGGAGGGTTCCCCCTTTC-3'
pcDNA4MH-mmPlxdc1 pcDNA4MH-hPlxdc1 5'-GGTACCAAGCTTAACTAGCCAGC-3' 5'-GCTGGCTAGTTAAGCTTGGTACCATGCGGGGCGAGCTCTGGC-3'
5'-AATCCCTATGCAGGAGGAGACGGC-3' 5'-GCCGTCTCCTCCTGCATAGGGATTCGACTTGGTGTCATCTTCTGTG-3'
pcDNA4MH-mmPlxdc2 pcDNA4MH-hPlxdc2 5'-GGTACCAAGCTTAACTAGCCAGC-3' 5'-GCTGGCTAGTTAAGCTTGGTACCATGGCGAGGTTCCCGAGGGC-3'
5'-GCCACAGCCATTCTTGTGACAGTC-3' 5'-GACTGTCACAAGAATGGCTGTGGCTATAATGAGGACCAGGATGAGG-3'
pLenti-CMV-Blast Plxdc1-Strep pLenti-CMV-Blast-EphA7-Strep 5'-AAAAAAGCAGGCTCCACCATGCGAGGCGAGCTCTGGCTC-3' 5'-TCTAGAAGCGCTTGGAGCCATCC-3'
5'-TGTGGATGGCTCCAAGCGCTTCTAGAGCACTGCTCAGCCTCCATG-3' 5'-CATGGTGGAGCCTGCTTTTTTGTAC-3'
pLenti-CMV-Blast Plxdc2-Strep pLenti-CMV-Blast-EphA7-Strep 5'-AAAAGCAGGCTCCACCATGGCGAGGTTCCCGAAG-3' 5'-TCTAGAAGCGCTTGGAGCCATCC-3'
5'-TGTGGATGGCTCCAAGCGCTTCTAGAGCACTGCTCTGATACAATAAAG-3' 5'-CATGGTGGAGCCTGCTTTTTTGTAC-3'
Around-the-horn pcDNA6V5-RRV 17577 gHΔ21-27 pcDNA6V5-RRV 17577 gH 5'-TCCAACGTCGAGCTGGAATTC-3'
5'-TTTGTCGGTCACGCTGCACCG-3'
pcDNA6V5-RRV 17577 gHY21A pcDNA6V5-RRV 17577 gH 5'-CGCTTTGTCGGTCACGCTGCACCG-3'
5'-GTGTACGACGAGAAGTCCAAC-3'
pcDNA6V5-RRV 17577 gH V22A pcDNA6V5-RRV 17577 gH 5'-TACGACGAGAAGTCCAACGTC-3'
5'-CGCGTATTTGTCGGTCACGCTGC-3'
pcDNA6V5-RRV 17577 gH Y23A pcDNA6V5-RRV 17577 gH 5'-GACGAGAAGTCCAACGTCG-3'
5'-CGCCACGTATTTGTCGGTCACGC-3'
pcDNA6V5-RRV 17577 gH D24A pcDNA6V5-RRV 17577 gH 5'-GAGAAGTCCAACGTCGAGC-3'
5'-CGCGTACACGTATTTGTCGGTCAC-3'
pcDNA6V5-RRV 17577 gH E25A pcDNA6V5-RRV 17577 gH 5'-AAGTCCAACGTCGAGCTGG-3'
5'-CGCCCGACAAATACGTGTACGAC-3'
pcDNA6V5-RRV 17577 gH K26A pcDNA6V5-RRV 17577 gH 5'-TCCAACGTCGAGCTGGAATTC-3'
5'-CGCCTCGTCGTACACGTATTTGTC-3'
pcDNA6V5-RRV 26-95 gHΔ21-27 pcDNA6V5-RRV 26-95 gH 5'-Phos/GTGCCTGGCCTGGAGATTGTC-3'
5'-Phos/GCCGTTAATTACAGAAAGTGTAATC-3'
pcDNA6V5-RRV 26-95 gH Y21A pcDNA6V5-RRV 26-95 gH 5'-CGCGCCGTTAATTACAGAAAG-3'
5'-GAATATAATGAGGAGAAGGTG-3'
pcDNA6V5-RRV 26-95 gH E22A pcDNA6V5-RRV 26-95 gH 5'-CGCGTAGCCGTTAATTACAG-3'
5'-TATAATGAGGAGAAGGTGCC-3'
pcDNA6V5-RRV 26-95 gH Y23A pcDNA6V5-RRV 26-95 gH 5'-CGCTTCGTAGCCGTTAATTAC-3'
5'-AATGAGGAGAAGGTGCCTGG-3'
pcDNA6V5-RRV 26-95 gH N24A pcDNA6V5-RRV 26-95 gH 5'-CGCATATTCGTAGCCGTTAATTAC-3'
5'-GAGGAGAAGGTGCCTGGCC-3'
pcDNA6V5-RRV 26-95 gH E25A pcDNA6V5-RRV 26-95 gH 5'-GGCATTATATTCGTAGCCG-3'
5'-GAGAAGGTGCCTGGCCTGG-3'
pcDNA6V5-RRV 26-95 gH E26A pcDNA6V5-RRV 26-95 gH 5'-GGCCTCATTATATTCGTAGCC-3'
5'-AAGGTGCCTGGCCTGGAG-3'
pcDNA6V5-RRV 26-95 gH K27A pcDNA6V5-RRV 26-95 gH 5'-GGCCTCCTCATTATATTCGTAG-3'
5'-GTGCCTGGCCTGGAGATTG-3'
Western Blot Target Species concentration Manufacturer
primary antibodies/ V5 tag/ PK tag SV5-Pk1 mouse 1:2000 Bio-Rad
detection c-myc 9E10 mouse 1:1000 Santa Cruz Bio
c-myc C3956 rabbit 1:4000 Sigma-Aldrich
DYKDDDDK tag (Flag) D6W58 rabbit 1:5000 Cell Signaling Technology
GAPDH [Biotin] A00915 goat 1:2000 genscript
StrepTactin-HRP conjugate (also 
secondary antibody for GAPDH-Biotin)
2-1502-001 1:5000 IBA
secondary mouse donkey 1:20 000 Jackson ImmunoResearch
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IV DISCUSSION and OUTLOOK 
 
IV.1 Key findings  
 
The manuscripts that constitute the present thesis further define communalities and 
differences between KSHV and RRV receptor usage by 1) characterizing a conserved motif on the 
rhadinoviral gH essential for binding to members of the Eph family of receptor tyrosine kinases, 2) 
defining additional A-type Ephs on BJAB cells, a model B cell line, as cellular receptors for cell-to-cell 
transmission of KSHV and cell-free infection of RRV and 3) identifying Plexin domain containing 




Figure 7 Graphic depiction of key findings that contribute to elucidation of rhadinoviral receptor usage 
and entry. Background colors indicate individual manuscripts. 
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IV.2 Determinants of affinity and receptor usage 
 
The importance of the Eph receptor family for rhadinoviral infection of a range of adherent 
target cells as well as the region mediating this interaction on EphA2, as prototypic KSHV gH/gL 
interactor have been demonstrated
86,143–150,247
. However, the crucial Eph-binding domain or motif on 
the viral gH/gL complex remained elusive. Due to the frequent co-expression of multiple Eph 
receptors on established cell lines the summed up contribution of Eph receptors to viral entry is hard 
to asses by knockdown or inhibition of single Eph family members. Another possible problem is the 
lack of adequate tools for the targeting and detection of proteins of interest (e.g. specific antibodies), 
which we encountered in case of Plxdc2
249,250
. Disruption of the essential receptor-binding motif on 
the viral glycoprotein would allow circumventing these restrictions while excluding possible 
bystander effects of inhibitory molecules or decoy receptors. To facilitate this approach, we mapped 
independent, minimal amino acid motifs on KSHV and RRV gH that are crucial for the interaction with 
Eph family receptors and Plxdc receptors, respectively, providing the basis for future studies on the 
contribution of Eph and Plxdc receptor interactions to cell and tissue tropism as well as to virus-
induced signaling. 
While mutation or deletion of the described motifs abrogates the interaction with the 
corresponding receptor family, different affinities for distinct members of these families displayed by 
KSHV and RRV or even RRV isolates 26-95 and 17577
247
 indicate the existence of additional regions in 
gH or gL that shape the observed binding preferences.  
Our study identified two key residues, RRV 26-95 gH Tyr23 and Glu25, which appear to be 
critical for the interaction of RRV isolate 26-95 with Plxdc1 and Plxdc2 (Publication 3). Even though 
these amino acids are conserved between RRV isolate 26-95 and isolate 17577, RRV 17577 selectively 
binds to Plxcd2 and not Plxdc1. Additionally, in contrast to RRV 26-95, this interaction is gL-
dependent. Similarly, albeit mutation of two amino acids (KSHV gH Glu52 and Phe53, RRV gH Glu54 
and Phe55) in the conserved rhadinoviral “ELEFN” motif is sufficient to completely disrupt the gH/gL 
interaction with both A-type and B-type Eph receptors, KSHV and RRV exhibit unique preferences for 
members of either receptor class. Furthermore, the recently described interaction of EBV gH/gL with 
EphA2 is clearly mediated by distinct binding sites, as the “ELEFN” motif is only partially conserved 
(“DIEGH”) in EBV gH
226,227
. Which additional regions determine the preference of individual receptors 
and if they in turn impact virus biology, by influencing e.g. cell and tissue tropism, spread or 
pathogenicity has yet to be determined.  
However, even if KSHV and RRV bind distinct high affinity Eph receptors, recent studies using 
adherent cell lines indicate that experimental overexpression of Eph receptors with comparable 
lower affinity for KSHV gH/gL (e.g. EphA4 and EphA5) can functionally substitute for EphA2 in KSHV 




. Our study addressing the role of Eph receptors for rhadinoviral infection of B cells – 
the major reservoir of latent KSHV in vivo – now provides evidence that these additional, lower 
affinity gH/gL-Eph interactions, here shown for EphA7 and EphA5, can also mediate KSHV and RRV 
entry at endogenous protein levels (Publication 2). Naturally, besides differences in affinity, more 
basic factors such as the availability, e.g. expression levels of distinct Eph receptors, may influence 
the cell type-dependent receptor usage. However, the notion that any of the KSHV gH/gL-interacting 
Eph receptors could potentially substitute for EphA2 was rendered unlikely by a recent study 
demonstrating that knockout of endogenous EphA4 led to an increase in KSHV infection
143
, which 
indicates differential properties of individual Ephs in rhadinoviral entry.  
To integrate the whole complexity of Eph family receptors, additional studies – preferentially 
addressing endogenous Eph receptors with loss-of-function methodology – are needed to evaluate 
the role of specific Eph receptors in shaping rhadinovirus cell tropism, the selective Eph 
receptor-induced downstream signaling as discussed below as well as the possible impact of the 
interaction with different Ephs on disease establishment and progression. 
 
IV.3 Determinants of rhadinovirus tropism 
 
As the cellular origin of KSHV-associated pathologies is still under discussion, identifying 
determinants that shape the cell and tissue tropism of KSHV in vitro and in vivo could help elucidate 
initial target cells, and potential starting points for interventions and therapies. 
A clear correlation between KSHV/ RRV receptor usage and cell tropism as seen for EBV
251,252
 
and human cytomegalovirus (HCMV)
253–256
 has not become apparent yet. In EBV infection for 
instance, the gH/gL complex acts as determinant of tropism through either direct interaction with the 
epithelial cell receptor EphA2 or through viral gp42-dependent interaction with the B cell-specific 
HLA class II receptor
257
. Similarly, heteromeric glycoprotein complexes of gH/gL with different 
interaction partners govern the cellular tropism of HCMV. While the trimeric complex comprising 
gH/gL and the β-herpesvirus-specific gO is thought to primarily enable PDGFRα-dependent cell-free 
infection of fibroblasts and contribute to cell-free PDGFRα-independent infection of epithelial and 
endothelial cells, the pentameric gH/gL/UL128/UL130/UL131 complex is required for efficient 
infection of leukocytes, dendritic cells and enhances infection of endothelial and epithelial cells
258–261
. 
The recombinant virus strains described herein allow us to address the question whether 
individual receptor interactions shape rhadinoviral tropism to a similar degree or if different receptor 
families exert redundant functions. For instance, the presented studies provide evidence for a more 
prominent role of the Eph-gH/gL interaction in RRV infection of lymphatic endothelium than 
fibroblasts (Publication 1) and identify cell lines that are primarily dependent on Eph receptors (e.g. 
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Raji, MMB1845) or Plxdc receptors (MFB5487) for RRV infection (Publication 3). However, as Raji, 
MMB1845 and MFB5487 all express B cell markers, it remains to be determined how these results 
transfer to RRV cell type tropism in vivo. A definite clarification how specific receptors contribute to 
rhadinoviral cell and tissue tropism requires – besides detailed knowledge about virus-host 
interactions – a more adequate modelling of the in vivo situation than what is currently achieved by 
established cell culture systems. Prominent issues are the limited availability of or knowledge about 
potential cell subtypes and changes induced upon immortalization or transformation of cell lines, 
which could particularly influence expression of tumor-associated receptors such as Ephs and Plxdcs. 
The problem is illustrated by our results on the usage of EphA7 as KSHV/ RRV receptor on BJAB cells. 
While BJAB cells are widely used as in vitro model for B cells, results obtained in this – or other cell 
lines – may not be easily transferable. For instance, while BJAB cells express both EphA7 and EphA5 
to detectable levels (Publication 2), studies on the expression of Eph receptors on mature B cells 
suggest that only EphA4 is consistently expressed in freshly isolated or cultured B cells from 
peripheral blood and lymph nodes
262
. While this further argues that in vitro experiments might not 
reliably predict tropism in vivo, data on receptor usage could give important hints regarding in vivo 
target cells. During B cell commitment and differentiation, EphA5 and EphA7 expression was only 
described in primitive CD34
+
 hematopoetic stem and progenitor cells (HSPC) and is lost after lineage-
commitment
263
. Given the observed persistence of KSHV infection in CD34
+
 HSPCs after 
differentiation into CD19
+




 and the role of EphA5 and EphA7 in 
KSHV cell-to-cell transmission into BJAB cells described in this work, EphA5 and EphA7 expressing 
CD34
+ 
HSPCs represent a candidate population for KSHV target cells in vivo which might be 
implicated in pathogenesis as well. Even though to date, KSHV-MCD and PEL are thought to originate 
at the stage of naïve B cells or possibly in a population of IgM memory B cells, further studies 
additionally addressing a potential reservoir formation at e.g. very early stages of hematopoetic cell 
development are necessary for a definite conclusion.  
 
IV.4 Animal models in rhadinovirus research and vaccine vector development 
 
To date, RRV infection of rhesus macaques is the most widely used animal model for KSHV 
pathogenesis and development of rhadinovirus vaccines and vaccine vectors. RRV infection reflects 
aspects of KSHV biology both on the scale of the whole host organism and the level of single 
molecule interactions which is exemplified in the conserved crucial Eph interaction motif 
(Publication 1) and the conserved EphA7 usage for infection of BJAB cells (Publication 2). However, 
the present manuscripts also underline divergences, e.g. the binding preferences of KSHV and RRV 
for distinct Eph receptors as well as the use of the Plxdc family for entry of RRV, but not KSHV. 
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Furthermore, the stark divergence in the susceptibility of BJAB cells for cell-free infection of RRV but 
not KSHV could hint to fundamental differences in either the natural target cells or the entry 
processes of both viruses. As KSHV and RRV belong to the RV1 and RV2 rhadinovirus lineage, 
respectively, the characterization of non-human primate viruses of the RV1 lineage, such as 
retroperitoneal fibromatosis viruses from different macaque species
39
 or the colobine 
γ-herpesvirus 1
40
 as potential alternative KSHV in vitro and in vivo models could prove informative for 
future studies. 
The relevance of in vivo validation of cell culture experiments in general was strikingly 
emphasized by the pre-vaccination study our group performed in cooperation with the Desrosiers 
group. In vitro, RRV enters BJAB B cells in an Eph-dependent manner and infection can be inhibited 
by competition with soluble Eph receptors
247
 or by Eph receptor knockdown as we demonstrated for 
EphA7 (Publication 2). Similarly, an Eph-detargeted gL-deficient RRV mutant (RRV ΔgL), which was 
characterized in detail on adherent cells (Publication 1), did exhibit a drastically attenuated 
phenotype on B cells of human and rhesus macaque origin
245
. However, after high-dose intravenous 
inoculation, a RRV strain, similarly disrupted in gL expression and harboring the SIV-gag protein as 
vectored antigen readily established persistent infection, elicited robust anti-RRV antibody and 
gag-specific T cell responses and colonized the CD20
+
 B cell compartment with comparable efficiency 
as wild-type RRV virus in experimentally or naturally infected rhesus macaques
245
. Consequently, 
albeit technical advances in cell culture and organotypic systems allow for increasingly complex 
experimental approaches the unique features of animal models should not be disregarded. 
An interesting example for the relevance of animal experiments not only in validating in vitro 
data but also in opening new directions for subsequent research projects is the use of attenuated 
rhesus CMV (RhCMV) as vaccination vector for HIV/SIV. Classical CD8
+
 T cell recognition is restricted 
by major histocompatibility complex (MHC) I and limited to few immunodominant antigen epitopes 
which do not facilitate protection against pathogens with efficient immune evasion such as 
HIV/SIV
265
. A series of studies demonstrated that a 68-1 RhCMV strain expressing SIV Gag, 
Rev/Nef/Tat, Pol, and Env elicits high-frequency effector-memory T cell responses with broad 
epitope-targeting and unconventional MHC restriction
266–268
. Subsequently, the molecular basis for 
these distinct, unconventional T cell responses was pinpointed to a lack of UL128 and UL130
265
 which 
are necessary to form the pentameric complex – the major determinant of CMV tropism as described 
above – while the dominant presentation of non-canonical antigen epitopes depends on the 
expression of CMV US11
265
.  
This example not only illustrates the importance of animal models for the development of 
antiviral strategies but also demonstrates that a detailed understanding of the molecular 
mechanisms of virus-host interactions during attachment and entry – the earliest steps in the viral 
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life cycle – is of critical importance for both, the design of intervention strategies (e.g. neutralizing 
antibodies or small molecule inhibitors) and the rational design of herpesvirus vaccines or their 
potential use as vaccine vectors. Rhadinoviruses per se represent a promising vector system as they 
can elicit strong T cell responses to vectored antigens – demonstrated in the aforementioned study 
in cooperation with the Desrosiers Group
245
 – and are non-pathogenic in healthy hosts. However, to 
increase the safety and exclude the development of KSHV-associated malignancies, rhadinovirus 
strains which are de-targeted from potential disease-contributing cell types should be used. The data 
on receptor usage on different cell types and receptor-binding motifs in the present manuscripts can 
therefore provide a basis for further studies concerning the potential development of rhadinoviruses 
as vaccine vectors. 
 
IV.5 Rhadinovirus mutants as probes for receptor-induced signaling  
 
A number of studies from a single lab addressed the induction of early signaling events upon 
KSHV binding and entry. Yet, several questions such as the distinct contribution of individual 
glycoprotein-receptor interactions to the temporal and spatial regulation of signaling cascades in 
different cell types remain unanswered. For instance, activation of the FAK/Src/PI3K pathway was 
initially attributed to the interaction of KSHV gB with integrin α3β1
162
. Consequently, soluble KSHV gB 
was shown to be sufficient for the induction of Src and PI3K phosphorylation and recruitment of 
downstream effectors in human foreskin fibroblasts (HFF), while KSHV gB, mutated in the classical 
RGD motif failed to do so
162
. Subsequent studies of the same group showed a reduction of KSHV-
induced phosphorylation of Src and PI3K upon knockdown of EphA2 (e.g. approx. 80% reduction of 
p-PI3K levels in shEphA2 transduced cells) in human dermal microvascular endothelial cells 
(HMVEC-d) and postulated the gB-dependent integrin signaling as upstream event of EphA2-
dependent signal amplification
144
. Interestingly, while crosstalk between EphA2 and integrins has 
been proposed in various systems, current literature indicates the activation of Eph receptors by 
ephrin ligands as upstream event of integrin-mediated signaling
269–271
. For instance, a recent study 
linked ephrinA1-EphA2 mediated phosphorylation of Src with spatially divergent FAK activation and 
formation of integrin/Src/FAK/paxillin complexes in focal adhesions
219
. While recruitment of a large 
number of signaling molecules into multimolecular complexes upon KSHV infection has been 
suggested
141,144–146,164
, it is not clear which virus-receptor interaction initiates these complex signaling 
events, which interactions are crucial, which interactions only amplify virus entry and productive 
infection or if there are even any interactions that are strictly essential. As different studies used 
different cell types, which were proposed to vary in the route of KSHV infection (clathrin-mediated 
endocytosis was described in HFF
85
 and Human umbilical vein endothelial cells (HUVEC)
92
, 
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), the role of Eph receptor interaction 
should be addressed regarding different uptake pathways as well as additional cell types with roles in 
KSHV pathology. In this context, the question whether KSHV-interaction with additional Eph 
receptors, e.g. EphA5 and EphA7 on BJAB cells (Publication 2), induces signaling responses similar to 
EphA2-dependent events would also be of interest. Furthermore, it would be useful to compare Eph 
signaling upon KSHV infection with described canonical and non-canonical Eph pathways. While KSHV 
gH/gL was shown to interact with the ligand-binding domain of EphA2
149
, which would be consistent 
with activation of the canonical signaling pathways similar to ephrin molecules, a recent study
148
 
stressed the importance of the non-canonical EphA2 Ser897 phosphorylation, induced upon KSHV 
infection, for virus entry (Figure 6). As the non-canonical Ser897 phosphorylation is thought to be 
pro-oncogenic, this could link Eph receptors to the development of KSHV-associated proliferative 
diseases. Thus far the correlation of described EphA2-signaling upon KSHV infection with specific 
phosphorylation events is hard to assess, as the initial studies did not provide detailed information 
on the analyzed phosphorylation sites
145
. Unraveling the differential activation of EphA2 by KSHV and 
the impact of EphA2 sequence variants associated with KSHV infection and KS development
273
 could 
help guide future studies regarding the role of EphA2 in KSHV-associated tumorigenesis and provide 
a platform to extend these analyses to additional, EphA2-associated tumors. 
A potential problem in the analysis of virus-induced signaling lies in the application of suitable 
controls. Lytic replication and production of virus stocks releases a multitude of signaling molecules 
and ligands which are hard to eliminate or control for and can potentially activate a multitude of 
cellular signaling pathways complicating the evaluation of signaling events induced by distinct virus-
receptor interactions. The KSHV/ RRV strains mutated in the Eph receptor interaction motif as well as 
corresponding soluble glycoproteins, which do not interact with Eph receptors in comparison to wild-
type versions, constitute a perfectly controlled system to specifically analyze the contribution of Eph 
receptor engagement to cellular signal transduction both in infection and pathophysiology. 
A similar system could be used to shed light on potential signaling events upon binding of RRV 
gH to Plxdc receptors. Using glycoproteins from RRV isolate 26-95 and 17577, and corresponding 
constructs mutated in the Plxdc interaction motif, we can target either Plxdc2, or both Plxdc1 and 
Plxdc2 with perfectly matched controls. This system is of particular interest as most studies 
concerning the Plxdc family focus on their role as tumor marker, and mechanistic information on the 
physiological and pathophysiological role of Plxdc1/2 is still sparse.  
Similar to the Eph receptor family, Plxdc1 or tumor endothelial marker 7 (TEM7) was first 
identified in gene expression profiles of endothelial cells from colorectal cancer tissue
274
. In the 
following, overexpression of either Plxdc1 or Plxdc2 was demonstrated in a variety of solid tumors
275–
278,278–280
. Plxdc1 was identified as negative prognostic marker in gastric cancer
281
, osteogenic 






 and down-regulation of Plxdc1 significantly reduced tumor cell 
migration and invasion
281
 as well as tumor growth
285
, while Plxdc2 expression in different solid 
tumors was associated with radio- and chemo-resistance
278,279
 as well as poor prognosis
280
.  
The analysis of specific cellular alterations upon Plxdc receptor activation is complicated by the 





 and pigment epithelium derived factor (PEDF)
287
 have been suggested 
as interaction partners of Plxdc1/2, all three molecules interact with a variety of cellular proteins, 
which impedes the select analysis of Plxdc-dependent signaling. Furthermore, cortactin was 
characterized as an actin-associated, cytoplasmic protein
288
, making a role in the initiation of outside-
in signaling unlikely. The use of Plxdc-interaction deficient RRV gH compared to wild-type RRV gH 
could help to identify Plxdc-specific signaling cascades and even decipher differences between Plxdc1 
and Plxdc2 activation by using the Plxdc2-selectivity of RRV isolate 17577. 
In general, the apparent preference of pathogens for receptors which are implicated in tumor 
development or maintenance, as shown here for Eph and Plxdc receptors, could provide interesting 
new research questions. Several tumor-associated phenotypical alterations, e.g. regarding metabolic, 
transcriptional, and signaling networks have also been demonstrated in KSHV-infected cells, 
suggesting common mechanisms for both pathologies. As KSHV-infection is associated with the 
development of three proliferative diseases, these similarities are not surprising in itself. However, 
the question whether elevated expression of tumor receptors in itself is already favorable for cancer 
development and infection or whether their role in KSHV pathogenesis relies on activation of 
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